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ABSTRACT 
ENGINEERING THE NANO-BIO INTERFACE OF GOLD NANOPARTICLES 
FOR BIOMEDICAL APPLICATIONS 
SEPTEMBER 2016 
 
YING JIANG, B.S., ANHUI NORMAL UNIVERSITY 
 
M.S., INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES  
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Vincent M. Rotello 
Gold nanoparticles (AuNPs) have emerged as a promising platform for a myriad 
of biomedical applications, including sensing, drug delivery, and antibiotics. In this 
thesis, I have studied and engineered the interface of AuNPs with different biological 
systems, demonstrating a large variety of biomedical applications by modulation of these 
interfaces. My research was initially focused on systematically tuning the 
physicochemical properties of nanoparticles to understand nano-bio interactions at the 
cellular level. The results demonstrate that size and surface charge of AuNP interact in an 
interrelated fashion to modulate nanoparticle internalization by cells, providing an 
engineering strategy for designing nanomaterials for drug delivery applications. Later, I 
engineered an environmentally responsive nanoparticle-protein interface for real time 
hydrogen peroxide (H2O2) sensing and monitoring of cellular oxidative stress. The 
responsiveness of this system demonstrates the utility of co-engineering synthetic-
biological hybrid nanomaterials. Moreover, I developed gold nanoparticle-stabilized 
nanocapsules (NPSCs) for in vitro and in vivo gene delivery to enhance cancer therapy 
 viii 
and immunomodulation efficiency. Finally, I demonstrated the use of gold nanoparticles 
to combat with pathogenic bacteria. The NP surface ligand chemistry and activity 
relationship reveals a new aspect to designing and constructing antimicrobial 
nanoparticles. In summary, the findings in this thesis highlight that systematically tuning 
the physicochemical properties of nanoparticles provides a powerful means to control 
interactions with biological systems, enabling new biological and therapeutic 
applications. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. An Overview of Nanoparticles in Biomedical Applications  
The field of nanotechnology involves the synthesis of new materials, with 
dimensions ranging from less than ten to hundreds of nanometers, and investigating the 
functional application of these materials. Since the late 1980s, researchers have 
developed efficient ways to prepare a variety of inorganic nanoparticles with excellent 
control over size, shape, and morphology. The original interests in these nanoparticles 
were primarily focused on exploring the predicted quantum size effects, with 
corresponding applications initially centered on physics, optics, and engineering.
1 , 2 With advances in tailoring the physical and surface chemistry properties of 
nanoparticles, a deeper understanding of their atomic structure, and controlling the 
interface of nanoparticles with biology, the functional application of nanomaterials has 
entered a new era of nanomedicine and nanobiotechnololgy (Table 1.1).3, 4, 5, 6, 7 
Nanoparticles, with size varying between 1 to 100 nm in particular, have unique 
characteristics that are favorable for probing and regulating numerous biological 
processes. These ‘tiny’ materials are essentially commensurate with various 
biomacromolecules including proteins and DNA, therefore hold promise for mimicking 
individual protein structure and function, a challenging prospect with “small molecule”-
based systems.8, 9 Moreover, the high surface-to-volume ratio of the NPs, coupled with 
the facile tuning of surface properties, provides effective surface area and produces 
receptors in a highly divergent fashion. Given this foundation, many nanomaterials have 
been used in a broad spectrum of highly innovative applications ranging from 
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chemical/biological sensing, 10 , 11  imaging, 12 , 13  cancer treatment, 14 , 15  and drug 
delivery. 16 , 17  Even more recently, the delivery of antibiotics, using engineered 
nanoparticles, has also become an emerging, realistic area of research.18, 19 Nanoparticle-
based antibiotic-carriers have been engineered to overcome antibiotic resistance that was 
developed with the use of traditional antibiotics.20 With these new technologies evolving, 
the interface between nanomaterials and biological systems merge into a new science that 
is concerned with the safe use of nanotechnology and nanomaterial design for biological 
applications. Studying nano-bio interfaces allows the development of predictive 
relationships between structure and activity that are shaped by nanomaterial 
physicochemical properties.  
Table 1.1. Characteristics, ligands and representative applications for various 
metal and semiconductor materials. Adapted from reference 4. 
Core 
material Characteristics Ligands Applications 
Au Optical absorption, 
fluorescence and fluorescence 
quenching, stability 
Thiol, disulfide, 
phosphine, amine 
Biomolecular 
recognition, 
delivery, sensing 
Ag Surface-enhanced 
fluorescence 
Thiol Sensing 
Pt Catalytic property Thiol, phosphine, 
amine, isocyanide 
Bio-catalyst, 
sensing 
CdSe Luminescence, photo-stability Thiol, phosphine, 
pyridine 
Imaging, and 
sensing 
Fe2O3 Magnetic property Diol, dopamine 
derivative, amine 
MR imaging and 
biomolecule 
purification 
SiO2 Biocompatibility Alkoxysilane Biocompatible 
by surface 
coating 
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Monolayer-protected gold NPs (AuNPs) are one of the most promising 
nanoparticle types, showing high potential for biomedical applications.21, 22 Bulk gold is 
chemically inert, yet well-established synthetic methods allow researchers to prepare gold 
nanoparticles with controlled size, shape, and surface chemistry, offering particles with 
new and emergent attributes.23, 24 Additionally, gold metal has extremely low background 
concentration in biological systems, making it relatively easy to selectively quantify at 
the part-per-billion level in complex biological settings. Finally, AuNPs possess excellent 
optical properties at the nanoscale, enabling a wide variety of analytical techniques for 
tracking and imaging gold in biological samples, including cells and tissues.25, 26,  27,  28 
This chapter will be a brief introduction of the interface of AuNPs with biology at the 
nanoscale, the study of nanoparticle parameters that modulate such interfaces, and the 
applications of AuNPs in medical and biological research. 
1.2. Cellular Uptake of Gold Nanoparticles 
Nanoparticles have been widely used for intracellular delivery of a diverse range 
of therapeutics, including small molecular drug,29, 30 genes,31, 32 and proteins.33, 34 Of the 
various nanoparticles that have been utilized for intracellular delivery, gold nanoparticles 
represent the most promising candidates for cellular delivery by showing high clinical 
translation potential.35, 36 This is mainly due to their low toxicity, biocompatibility and 
tunable surface functionalities. One of the factors that determines the efficiency and 
efficacy of intracellular delivery with gold nanoparticles is the interaction of 
nanoparticles with cells and the cellular uptake. 37 , 38  Therefore, understanding the 
underlying mechanism and pathways of gold nanoparticle uptake by cells is important 
towards developing nanoparticles for optimal intracellular delivery, interpreting the 
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biological fate of nanoparticles, and most importantly, to precisely control their delivery 
capacity for advanced biomedical applications. 
Currently, it is well known that the physicochemical properties of nanoparticles, 
including the size, 39 , 40  shape, 41 , 42  surface charge, 43 , 44  and functionality, 45 , 46 
comprehensively determine the interactions of NPs with physiological systems. Recent 
studies have generally attempted to correlate the NP and cell interactions with the 
physical and structural properties of NPs on a case-by case basis, looking at one 
parameter while keeping others constant. For example, nanoparticle size is the key 
determinant of particle uptake inside the cells, with 50 nm nanoparticles exhibiting the 
highest cellular uptake efficiency among a set of AuNP ranged in 14-100 nm.47 The 
similar size preference in the cellular uptake of AuNPs is also observed for other types of 
nanoparticles, and is considered to occur due to the fine balance between the multivalent 
crosslinking of membrane receptors and the membrane wrapping involved in receptor-
mediated endocytosis (Figure 1.1).38  
 
Figure 1.1. Illustrations of ErbB2 receptor localization after treatment with different-
sized Her–GNPs. Adapted from reference 38. 
 
 5 
The shape of the gold nanoparticle is another important factor that affects the 
uptake pathway and efficiency. Zhao et al. studied the influence of the geometrical 
parameters of Au nanorods (NRs) on their cellular uptake, and found that spherical 
nanoparticles of similar sizes or shorter NRs with similar surface charges were 
internalized more easily and efficiently than rod-shaped and longer NRs. This is 
attributed to the shorter membrane wrapping time required for the spherical-shaped 
particles to enter cells.48 
 In a similar fashion, Rotello et al. and others have found that relatively small 
variations in surface chemistry (e.g., changes in ligand arrangement and charge 
orientation) as well as net changes in NP surface charge can significantly influence the 
rate and efficiency of cellular uptake (Figure 1.2). 49  For example, it is found that 
positively charged NPs are taken up more rapidly and efficiently than negatively or 
neutrally charged NPs. However, negatively charged NPs can also be efficiently 
internalized, presumably through pinocytosis or membrane diffusion.50 In addition, NP 
hydrophobicity and their interactions with plasma proteins also influence uptake. Rotello 
et al. have synthesized 2 nm core sized AuNPs libraries with systematically varied 
surface hydrophobicity, and investigated the effect of NP surface hydrophobicity on 
cellular uptake.51 They demonstrated that in the presence of serum proteins, hydrophobic 
nanoparticles bind serum albumin more tightly, which in turn decreases the cellular 
uptake of gold nanoparticles. However, in the absence of serum, there was no obvious 
correlation between uptake and surface hydrophobicity, suggesting the importance of 
evaluation of the collective impact of these parameters in dictating cellular internalization. 
In addition, the agglomeration and aggregation of nanoparticles in biological systems 
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changes the overall size/shape and surface charge of nanoparticles, which influences the 
cellular internalization pathway accordingly.52, 53, 54  
 
Figure 1.2. a) Structure of mixed monolayer-protected cationic and anionic gold NPs 
loaded with thioalkylated fluorescein isothiocyanate (FITC). Green fluorescence images 
of tumor cylindroids treated with b) cationic, and c) anionic particles. Adapted from 
reference 49. 
 
1.3. Gold Nanoparticles for Biological Sensing 
Gold nanoparticles possess several distinctive physical and chemical attributes 
that make them a promising synthetic scaffold for the creation of novel chemical and 
biological detection systems.12, 55, 10 In particular, AuNPs have extraordinarily high molar 
extinction coefficients (1×109 M−1 cm−1 for 20 nm sized AuNP) as compared to common 
organic dyes (104-106 M−1 cm−1), allowing the highest sensitivity in the development of 
optical probes.12 Additionally, their absorbance is dependent on the size and shape of NPs 
and varies with their surrounding chemical environment. 56 Moreover, AuNPs can be 
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easily functionalized with a wide range of biomolecules and targeting agents, which have 
been demonstrated to be effective in preventing non-specific interactions with interfering 
molecules and avoiding false-positive detection signals. 57 , 58  Taken together, these 
attributes have prompted the design of gold nanoparticle based fluorescent probes that 
offer significant advantages in terms of sensitivity, selectivity, reliability, and practicality.  
 
Figure 1.3. Aptamer nano-flares are gold nanoparticles functionalized with thiol-
terminated aptamer sequences hybridized to a short complementary Cy5-labeled reporter 
strand. The reporter is capable of being displaced by a conformation change in the 
aptamer that is induced by the target molecule. Adapted from reference 59.  
 
An AuNP-based fluorescence turn-on assay has been developed to detect ATP 
inside living cells.59 In this method, AuNPs were functionalized with a dense monolayer 
of ATP-binding aptamers hybridized with short complementary Cy5-labeled reporter 
strands. In the absence of ATP, the fluorescent Cy5 dye remains close to NP surface, 
resulting in quenched fluorescence (Figure 1.3). After binding with ATP inside living 
cells, the conformational change of aptamers displaces the Cy5-labeled strand from the 
NP surface, which subsequently restores fluorescent emission from Cy5. By quantifying 
the fluorescence intensity, it is possible to determine intracellular ATP concentration. 
Similar strategyies has been adapted to develop sensors for a wide range of analytes, 
including metal ions, small molecules, proteins, and nucleic acid biomarkers.60, 61, 62  
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Figure 1.4. Fluorescence sensing for measuring the distance between two receptor PTK7 
binding sites on a live cell membrane. Adapted from reference 63. 
 
Recently, Tan et al. created an AuNP/aptamer fluorescence probe to sense 
molecular interactions at the cell surface (Figure 1.4). 63 In this report, sgc8 aptamer 
modified AuNPs, and Alexa Fluor® 488 labelled anti-PTK7 antibody constituted a 
fluorescence resonance energy transfer (FRET) acceptor and donor pair, respectively. 
When these two components bind onto the cell surface receptor in close proximity, 
efficient quenching of Alexa Fluor® 488 fluorescence is observed.  By controlling the 
size of the AuNPs, the FRET efficiency is subtly manipulated, providing fluorescence 
readout of the distance between two binding sites on live cell membrane.  
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Figure 1.5. a) Fabrication of the three-channel nanosensor (BenzNP–FP complex). b) 
Schematic illustrating the displacement and fluorescence turn-on of fluorescent proteins 
by cellsurface functionalities. c) Differential affinity of BenzNP to tdTomato (red), 
EBFP2 (blue) and EGFP (green) protein. d) Screening of chemotherapeutic drug 
mechanisms using fluorescence fingerprints. Adapted from reference 67. 
 
Apart from incorporating selective recognition units (e.g., aptamer) onto AuNPs 
surfaces, the Rotello group has pioneered the use of AuNPs and fluorescent molecules for 
biosensing, known as the “chemical nose” approach.64, 65, 66 In a typical chemical nose 
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assay, a sensor array is fabricated using cationic AuNPs, with various headgroups, and 
anionic fluorescent polymer or proteins that serves as the fluorescence transduction 
element. The cationic AuNPs act to significantly quench the intrinsic fluorescence of the 
polymer or proteins. Competitive binding of the analyte releases the polymer or proteins 
from the NP surface, generating a characteristic fluorescence ‘turn-on’ signal. This 
approach has been used for identification between healthy, cancerous, and metastatic 
cells. More recently, an array of gold nanoparticles complexed with three different 
fluorescent proteins has been designed as a high-throughput multichannel sensor platform 
to profile the mechanisms of various chemotherapeutic drugs in minutes (Figure 1.5).67 
1.4. Gold Nanoparticles based siRNA Delivery68 
 
AuNPs have excellent physical and chemical properties that make them perhaps 
the most studied inorganic NPs for siRNA delivery and gene expression 
regulation.69, 70, 71 First, the core of AuNP is essentially inert, nontoxic, and biocompatible, 
thus enabling a stable and safe siRNA delivery. Second, the well-developed surface 
chemistry of AuNPs allows efficient encapsulation of siRNA via either covalent or non-
covalent conjugation. Finally, the ability to “tune” AuNP properties through surface 
modification provides convenient approaches for controlling NP delivery and 
intracellular siRNA release. 
1.4.1. Covalent Conjugation of AuNP/siRNA 
A common approach for siRNA delivery involves the covalent conjugation of 
siRNA with various cell-penetrating or targeting ligands, such as lipids,72 peptides,73 and 
small molecule receptors. 74  These conjugates have shown effectiveness for siRNA 
delivery, with GalNAc-conjugated siRNA exhibiting promising results in silencing 
targeted gene in clinical trials.75 However, these siRNA conjugates usually lack serum 
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stability and have a short circulation time which prohibits a long term gene silencing 
effect. NP-based siRNA delivery approaches have shown superior stability against 
enzymatic degradation, and additionally prevent the premature release of siRNA into the 
physiological environment that can occur using other siRNA conjugates. 
The most direct method to use AuNPs for siRNA delivery is to conjugate siRNA 
onto AuNP surface via thiol-gold covalent chemistry. Nagasaki et al. first used siRNA-
AuNP conjugates for siRNA delivery in 2006.76 They modified 15 nm AuNPs with thiol-
PEG5000-PAMA7500 polymer, followed by self-assembling thiolated siRNA. The 
resulting AuNP/siRNA conjugates led to a 65% gene silence efficiency with human 
hepatoma HuH-7 cells. Mirkin et al. has extended this concept to create spherical nucleic 
acid (SNA) nanoparticles (Figure 1.6a). The systemic administration of SNAs reduced 
Bcl2L12 expression in intracerebral glioblastoma multiforme, increased intratumoral 
apoptosis, and reduced tumor burden and progression in xenografted mice.77  
Covalent siRNA/AuNP conjugates can be further coated with cationic polymer or 
cell penetrating peptides to enhance siRNA delivery efficiency. For example, Reich et al. 
first conjugated thiolate siRNA onto a gold nanoshell surface, followed by coating the NP 
surface with a streptavidin layer used to attach cell penetrating peptides through biotin-
streptavidin ligation.78 Upon irradiation with biocompatible near infrared (NIR) light, the 
siRNA was released from the gold surface and escaped from the endosome. The siRNA 
construct was efficiently internalized by a broad range of human embryonic stem cells 
(hESC), knocking down of Oct4 induced the differentiation of hESC to all three germ 
layers. Anderson et al. conjugated thiol-siRNA onto amine-coated AuNP using a dual-
functional crosslinker, succinimidyl 3-(2-Pyridyldithio)Propionate (SPDP).79 The siRNA-
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AuNP conjugates were post-coated with biodegradable polymer, poly (β-amino ester), to 
improve siRNA gene silencing efficiency. The treatment of luciferase-expressing HeLa 
cells with 90 nM siRNA silenced gene expression in an efficiency higher than 90% in 
serum-containing medium. 
 
Figure 1.6. a) SNAs are 13-nm gold cores densely functionalized with highly oriented, 
thiolated siRNA duplexes that target GM3S. The SNA surface is passivated with 
oligoethylene glycol for colloidal stability. b) siRNA delivery using dendronized AuNPs. 
Chemical structure of G2-AuNP and schematic illustration of G2-AuNP/β-gal-siRNA 
complexation and transfection into SVR-bag4 cells. c) Enhanced intracellular payload 
release at endosome by pH-dependent charge-reversal polyelectrolyte on gold 
nanoparticles. Adapted from reference 68. 
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The ease of functionalization of AuNPs makes them excellent platforms for 
targeted delivery vehicles. For example, the simultaneous conjugation of thiol-siRNA and 
Arg-Gly-Asp (RGD) onto AuNP efficiently delivered siRNA to the tumor site in a lung 
cancer orthotopic murine model.80 Knocking down c-myc oncogene using this targeting 
siRNA/AuNP conjugate resulted in tumor growth suppression and prolonged survival of 
lung tumor bearing mice. The simplicity and versatility of the AuNP scaffold allows the 
creation of complex machinery. Kim et al. reported an i-motif-driven gold nanoparticle-
based nanomachine for programmed siRNA delivery. 81  They immobilized a pH-
responsive nucleic acid consisted of three functional segments, i.e., an i-motif DNA, 
which has an acid-responsive switchable secondary structure, an overhanging linker 
DNA, and a therapeutic siRNA, on the nanomechine. After entering cells, the acidic 
endosome environment triggers the formation of an interstrandtetraplex of i-motif to 
induce cluster formation of AuNP, which facilitates endosomal escape and releases 
siRNA into cytosol. The delivery of siRNA against polo-like kinase 1 (PLK1) 
significantly reduced the viability of NIH3T3 cells, suggesting the therapeutic potential 
of this strategy. 
1.4.2. Non-covalent Encapsulation of siRNA/AuNP 
Non-covalent delivery strategies provide a versatile modular strategy for the 
delivery of free siRNA. The negative charge of the siRNA strand facilitates assembly 
with positively charged NPs. For example, Rotello et al. have reported dendronized 
AuNPs for siRNA delivery (Figure 1.6b).82 AuNPs (2 nm core) were functionalized with 
dendronized ligands based onbiodegradable glutamic cores with cationic 
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triethylenetetramine (TETA) termini. The second generation of dendronized AuNPs (G2-
AuNPs) encapsulated siRNA with the highest efficiency. G2-AuNP delivered β-
galactosidase targeting siRNA (β-gal–siRNA) into SVR-bag4 cells, with knockdown 
efficiency up to 50%, as measured by enzyme activity assay. Cationic polymers, such as 
PEI and polylysine (PLL), have a long history as gene delivery vehicles. The direct 
functionalization of AuNP with these polymers enables encapsulation of siRNA and 
delivery. For example, Park et al. reported the controlled synthesis of PEI-coated AuNP 
using catechol-conjugated PEI for siRNA delivery.83 Also, PEI has been used as both 
reductant and stabilizer to synthesize AuNPs which have been used to silence GFP and 
oncogenic PLK-1 gene via siRNA delivery for cancer therapy.84 
 Layer-by-layer (LBL) coating of a gold core with cationic polymers and siRNA 
is another method for creating polymer-coated AuNPs for siRNA delivery. Negatively 
charged AuNPs were complexed with bPEI (25 kDa) and then sequentially deposited 
siRNA and bPEI to form AuNP/bPEI/siRNA/bPEI complexes, which showed an 
increased hydrodynamic diameter of 22~25 nm. On average, around 780 siRNA 
molecules were complexed with each AuNP, which was a significant enhancement 
compared to covalent siRNA-AuNP conjugates. The gene silencing efficiency of 
AuNP/bPEI/siRNA/bPEI complexes was verified by delivering siRNA against EGFP to 
CHO-K1 cells. 85  Hahn reported LBL assembled cysteamine (CM) modified AuNP 
(AuCM)/siRNA/PEI/hyaluronic acid (HA) for intracellular delivery of siRNA. 86  The 
introduction of HA into the NPs enabled the targeted delivery of siRNA to B16F1 cells 
which has HA receptors. The authors demonstrated the capability of 
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(AuCM)/siRNA/PEI/HA for in vivo siRNA delivery by knocking down apolipoprotein B 
expression in mouse liver. 
The use of biodegradeable biopolymers provides a means of reducing the toxicity 
of the carrier. For example, Tung et al. incorporated protease-degradable poly-lysine 
(PLL) and siRNA on the surface of AuNPs, and reported siRNA/PLL multilayer-coated 
AuNPs for siRNA delivery. 87  The PLL multilayer can be degraded by lysosomal 
cathepsin B enzyme to release siRNA gradually, inducing a prolonged gene-silencing 
effect. They later demonstrated that AuNPs with two layers of siRNA and three layers of 
PLL provided 20 days of > 60% luciferase knockdown in a MDA-MB-231-Luc 
xenograft. 88  More recently, ‘‘charge-reversal’’ polyelectrolytes have been applied to 
siRNA delivery. 
The ‘‘charge-reversal’’ polymer change net charge, from positive at neutral pH to 
negative under acidic environment efficiently controls siRNA release inside cells. For 
example, Liang et al. have used pH-responsive cis-aconitic anhydride-functionalized 
poly(allylamine) (PAH-Cit), and developed a ‘‘charge-reversal’’ LBL AuNP/siRNA 
delivery method (Figure 1.6c).89 AuNPs were initially modified with negatively charged 
11-mercaptoundecanoic acid (MUA), upon which bPEI was deposited forming a cationic 
AuNP-MUA/bPEI core for LBL assembly. PAHCit and bPEI were then sequentially 
deposited onto the AuNP-MUA/bPEI core to encapsulate siRNA. The assembled 
PEI/PAHCit/PEI/MUA-AuNP/siRNA shows improved endosome escape efficiency and a 
higher gene knockdown efficiency than commercial lipid reagents and bPEI. 
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Figure 1.7. Schematic illustration of the proton sponge effect leading to siRNA release 
into the cytosol. Adapted from reference 68. 
 
1.4.3. Strategies to Facilitate Endosome Escape and Cytosolic siRNA Delivery 
A key barrier to efficient siRNA delivery and effective RNAi is the delivery of 
siRNA cargo to the cytosol, where siRNA is loaded into the RISC to degrade mRNA. 
Nanomaterials usually enter cells via an endocytic pathway, resulting in endosome 
entrapment. It has been reported that even with relatively efficient vectors only a small 
fraction (1-2%) of internalized siRNA can escape from the endocytic pathway. 90 
Designing nanocarriers that facilitate endosome escape of siRNA, or directly deliver 
siRNA into cytosol is therefore highly desired for effective RNAi.91 One commonly used 
method to facilitate endosomal escape of siRNA is to design highly positively charged 
polyamine carriers, which enhance endosome escape capability through the “proton 
sponge effect” (Figure 1.7).69 These polyamine carriers, such as PEI and its derivatives, 
sequester protons when they enter the acidic lysosome compartment of cells due to the 
large buffering capacity of secondary or tertiary amines presented on the carriers. The 
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continuous protonation of polyamine carriers subsequently pump chloride ions into the 
endosome, causing a water influx that leads to endosomal swelling and lysis, releasing 
siRNA into the cytoplasm.91 However, a recent study revealed that the widely used PEI 
played a limited role on enhancing endosome escape even under strong acidic lysosomal 
environment.92 Introducing membrane-disruptive or fusogenic peptides such as GALA 
and KALA,93, 94 onto AuNP surface improves the endosomal escape of siRNA to certain 
extent, with improved gene knockdown efficiency. 
Alternatively, hollow AuNPs that can be heated with NIR light irradiation have 
facilitated escape of siRNA from the endosome. For example, Li et al. demonstrated that 
conjugates of siRNA targeting NF-KB p65 and hollow AuNP allowed for controllable 
cytoplasmic siRNA delivery upon NIR light irradiation.95 
1.5. Gold Nanoparticles-based Antimicrobials 
Pathogenic bacteria are a serious threat to public health, with acquired antibiotic 
resistance challenging the effectiveness of traditional antimicrobials.96, 97 Nanoparticles 
provide versatile platforms for fighting such infections, by possessing multiple attributes 
that facilitate new and unique therapeutic strategies.98, 99, 100, 101 For example, NP size 
can be precisely tuned to overwhelm the efflux-mediated extrusion of antibiotics, 
enhancing the drug concentration in bacteria.  In addition, the large surface area enables 
increased loading of therapeutics, with the potential for synergy resulting from 
multivalent presentation. Moreover, NPs are relatively stable against proteolytic enzyme 
degradation increasing the drug half-life of associated antimicrobial peptides. Finally, 
NPs can be easily modified with targeting functionalities to specifically attack biological 
targets, reducing potential toxicity to host cells.  
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AuNPs are chemically stable, size/shape-controllable, easily modifiable with 
desired molecules, and nontoxic to mammalian cells or animals, making them perhaps the 
most intriguing inorganic NPs for imparting antimicrobial efficacy.98, 102 For example, 
Bunz et al. reported that 6 nm cationic gold nanoparticles (AuNP) display strong 
antimicrobial efficiency by disrupting the bacterial membrane.103 Sabo-Attwood et al. 
demonstrated that gold nanorods can be covalently linked to primary antibodies to 
selectively target pathogenic Gram-negative bacterium.104 Following nanorod attachment 
to the bacterial cell surface, exposure to near-infrared radiation results in a significant 
reduction in bacterial cell viability. Alternatively, spherical gold NPs can be conjugated 
with a panel of small molecular-based antibiotics,105, 106 exhibiting pronounced efficacy 
against MDR bacteria. However, some requirements of antibiotic NPs might limit their 
applications; e.g., relying on external sources of energy, and depending on existing 
antimicrobial drugs for activity. 
Recently, Rotello et al. utilized the surface engineering of nanoparticles to 
provide both new therapeutics and information on the challenges in antimicrobial 
therapies.100, 107 In early studies of nanoparticle-microbe interactions, it was found that 
positively charged nanoparticles are toxic to bacteria, and this toxicity mainly arose from 
the ability of these nanoparticles to strongly interact and disrupt functionality at the 
bacterial cell surface. Later, they expanded ligand engineering to generate new 
antimicrobials that were broadly effective against pathogenic bacteria (Figure 1.8). 
Significantly, they did not observe resistance to antimicrobial NPs even after 20 cycles of 
sub-MIC dosing, far longer than required for bacteria to develop resistance to standard 
antibiotics.100 
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Figure 1.8. Nanoparticle therapeutics for MDR bacteria. a) Nanoparticles studied, 
featuring 2 nm gold cores. b) Toxicity of NPs to a laboratory E. coli strain. Adapted from 
reference 72. 
 
While antimicrobial activity of these nanoparticle-based antibiotics is high, it is 
unclear whether these systems have the ability to target bacterial infections, without 
harming host cells, an important prerequisite for therapeutic strategies. The future 
efficacy of nanoparticle based antibiotics rests upon the ability of nanoparticles to 
localize a high-concentration of drugs, reach a pre-determined target with high specificity 
and efficiency, elicit their antimicrobial activity in a controlled and timely manner, and 
without toxic effects to in vivo host cells. 
1.6. Dissertation Overview  
The significant advances in synthesizing nanoscale materials, coupled with 
tremendous efforts in understanding and controlling of biological systems, has prompted 
the disparate fields of nanotechnology and biological systems to come together. Gold 
nanoparticles serve an ideal candidate to bridge across the nano-bio interface arising from 
their excellent optical properties and their promising biomedical applications. In this 
thesis, AuNPs are used as a model platform to understand the interface of nanoparticles 
with biological systems, as well as monitor and regulate biological processes. 
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Correlation of the interactions of surface physicochemical properties 
nanoparticles with biosystems provides fundamental data for nanomedicine. In chapter 2, 
I have systematically synthesized 2, 4, and 6 nm core gold nanoparticles featuring neutral 
(zwitterionic), anionic, and cationic headgroups. The cellular internalization and 
mechanism associated with the uptake process of these AuNPs was determined, 
providing a parametric evaluation of charge and size effects.  
Integrating synthetic nanomaterials with biomolecules provides an important 
platform for chemical and biosensing. In chapter 3, I developed a gold 
nanoparticle/protein interface featuring a galactose headgroup (AuNP-Gal) that reacts 
covalently with a boronate-modified green fluorescent protein (PB-GFP). This interface 
can be modulated by peroxide, allowing selective, quantitative monitoring of H2O2 
production in real time. 
In Chapter 4, 5, and 6, I have demonstrated that gold nanoparticle stabilized 
nanocapsules provide a promising vector for siRNA delivery in vitro and in vivo. In this 
approach, siRNA is complexed with cationic arginine functionalized gold nanoparticles 
via electrostatic interactions, with the resulting ensemble self-assembled onto the surface 
of fatty acid nanodroplets to form a NPSC/siRNA nanocomplex. The siRNA-loaded 
nanocapsule is capable of delivering siRNA directly to the cytosol by bypassing 
endocytic pathways. NPSC/siRNA mediated knockdown of proteins that promote cancer 
survival and expansion or proinflammatory cytokines that regulate inflammatory activity 
offer an efficient tool for RNAi-based cancer therapy and immunomodulation.  
In addition to understanding, monitoring and regulating the biological processes 
of eukaryotic cells using gold nanoparticles, I have also demonstrated the use of gold 
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nanoparticles to combat pathogenic bacteria. In Chapter 7, I have demonstrated that 
zwitterionic gold nanoparticles can be used as potent antimicrobial agents against MDR 
bacteria by optimizing NP size and surface charge orientation. I further discuss the 
determined NP surface ligand structure-activity relationship, revealing a new aspect 
towards the design and construction of antimicrobial gold nanoparticles. 
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CHAPTER 2 
THE INTERPLAY OF SIZE AND SURFACE FUNCTIONALITY ON THE 
CELLULAR UPTAKE OF SUB-10 NM GOLD NANOPARTICL 
 
2.1. Introduction 
The physicochemical properties of nanoparticles, in particular size 1 , 2, 3, 4, 5 
shape,6, 7, 8 surface charge9, 10, 11, 12 and functionality,13, 14, 15 comprehensively determine 
the interactions of NPs with physiological systems.16, 17 Recent studies have generally 
attempted to correlate the NPs-cell interactions with the physical and structural properties 
of NPs on a case-by-case basis, looking at one parameter while keeping others constant.  
For example, the cellular uptake of nanoparticles was found to be strongly size-dependent, 
with 50 nm nanoparticles exhibiting the highest cellular uptake efficiency among a set of 
AuNP ranged in 10-100 nm.7 In similar fashion, we and other groups have found that the 
internalization of NPs is dictated by chemical functionalities on nanoparticle surface.9, 15  
Exploring NP behavior in biological contexts along a single structural parametric 
axis is clearly informative. Interplay is expected, however, between structural factors, e.g., 
size and surface properties in terms of the biological properties of nanomaterials. 
Examining the collective impact of these parameters in cellular internalization is crucial 
for generating effective tools for biomedical applications in delivery. For example, Chan 
et al. studied the roles of nanoparticle size (15, 30, 60, and 90 nm) and surface ligand 
grafting density on serum protein adsorption, showing how these attributes differentiated 
the pathway and efficiency of nanoparticle uptake by macrophage cells. 18 In another 
study, Toth et al. explored the effects of NP charge and size on the cellular uptake by 
changing the polymer coatings of AuNPs of 5, 10, and 20 nm sizes.14  
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Smaller (sub-10 nm) AuNP provide a particularly important set of particles for 
biomedical applications.3, 19, 20, 21, 22 Pragmatically, these particles provide high payload-
to-carrier ratios, with smaller particles in this regime capable of renal clearance.23  On a 
fundamental level, these particles are on a size scale commensurate with proteins, and 
can be engineered to provide highly biomimetic surfaces. 24 Practically, however, the 
small size of these NPs makes parametric evaluation of surface chemistry challenging, as 
polymeric coatings will induce more dynamic changes in size and dynamic properties to 
smaller particles.  
Here, we report the parametric fabrication of 2, 4, and 6 nm core AuNP featuring 
zwitterionic, anionic and cationic surface ligands. We correlated the cellular 
internalization efficiency of these particles and observed a striking difference in uptake 
trends. With cationic particles, increasing particle size resulted in increasing uptake. The 
opposite trend was observed for neutral zwitterionic and anionic particles, where uptake 
efficiency decreased with particle diameter. Mechanistic studies provide insight into 
these opposing trends. With cationic particles, active endocytotic pathways were 
responsible for the bulk of NP uptake. With the zwitterionic particles, however, passive 
diffusion appeared to be the predominant mechanism. More interestingly, small sized 
anionic NP (2, and 4 nm) entered cells through endocytic pathways to that of same sized 
cationic particles, while large sized anionic particles (6 nm) mainly displayed 
caveolae/lipid raft-mediated pathway. The results reported here demonstrate the 
importance of the interplay between size and surface functionality on dictating 
nanoparticle-cell interactions, and offer insight into engineering NP systems with 
predictable cell interactions.   
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Figure 2.1. Characterization of as-synthesized gold nanoparticles with different sizes (2, 
4, and 6 nm) and surface modification (cationic: TTMA, zwitterionic: SN and NS, and 
anionic: COOH). A) General structure of AuNP, with either interactive cationic and 
anionic or “stealth” zwitterionic headgroups appended to a noninteracting OEG-
functionalized interior. B) TEM images of 2, 4, and 6 nm core diameter AuNPs. C) UV-
vis absorbance spectra of the each of the particle families as a function of core size.  
 
2.2. Results and Discussion 
We designed structurally related NPs that featuring different surface charges to 
probe the effect of NP surface functionality on the cellular uptake of sub-10 nm AuNP. 
We first synthesized a set of cationic and anionic sub-10 nm AuNP coated with thioalkyl 
tetra(ethylene glycol)ated trimethyl ammonium (TTMA), and carboxylate ligands 
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(COOH), respectively. The tetra(ethylene glycol) spacer was added between the terminal 
positively or negatively charged group and the hydrophobic alkyl chain to enhance NP 
stability, and to improve the biocompatibility of AuNP. The third category of sub-10 nm 
AuNP in this study was coated with zwitterionic ligands. We generated two subfamilies 
featuring different positioning of the charged moieties (Figure 2.1A), the first has positive 
charges in outermost layer (SN), while the second ligand has innermost layer of positive 
charge (NS).  
 
Figure 2.2. LDI-MS spectrum of gold nanoparticles with A) TTMA (m/z 422.3), B) 
COOH (m/z 438.3), C) SN (m/z 601.1), and D) NS (m/z 530.2) ligand modifications. 
 
The particles were fabricated using 2 nm NPs protected with 1-dodecanethiol 
synthesized according to the Brust method,25 while 4 nm and 6 nm AuNP were grown 
from 2 nm dodecanethiol AuNP using heat-induced size evolution.26 These AuNP were 
then functionalized with TTMA, COOH or zwitterionic ligands via place exchange 
reactions. The successful NP surface functionalization was analyzed and confirmed using 
laser desorption/ionization mass spectrometry (LDI-MS, Figure 2.2). A molecular peak 
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observed at m/z value of 422.3 was ascribed to TTMA on NP surface, while peaks at 
438.3, 530.2, and 601.1 were attributed to COOH, NS, and SN ligands, respectively. The 
number of ligands on each particle surface was determined by matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS, Table 2. 1).  
Table 2.1. Ligand number of each nanoparticle determined by MALDI-MS 
Mean values ± standard deviation, N = 3. 
 
 
The size and morphology of all NPs were further characterized using transmission 
electron microscopy (TEM) (Figure 2.1B) and dynamic light scattering (DLS) analysis. 
As shown in Table 2.2, the hydrodynamic size of AuNP increased gradually when the 
core size of NP was increased from 2 nm to 6 nm. Meanwhile, the functionalization of 
AuNP with TTMA, COOH, or zwitterionic surface ligands had minor effect on AuNP 
size. Zeta potential measurements confirmed the positive, negative, and neutral charges 
of TTMA, COOH, and zwitterionic ligand-coated AuNP, respectively (Table 2.2). As 
expected, UV spectra of AuNP indicated a red-shifted surface plasma resonance (SPR) 
peak when NP core size  was increased from 2 to 6 nm, with no significant SPR band 
difference was observed between the same size AuNP coated with TTMA, COOH, and 
zwitterionic ligands (Figure 2.1C). 
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Our uptake studies used the widely employed human cervical carcinoma (HeLa) 
cell line, allowing the correlation of current study with prior reports. Preliminary studies 
indicated a low cytotoxicity of AuNP to HeLa cells at a NP concentration of 25 nM; this 
concentration was then fixed for the following NP uptake study (Figure 2.3).  
Table 2.2. Dynamic light scattering analysis and zeta-potential measurements 
of as-synthesized nanoparticles in 5 mM phosphate buffer (pH = 7.4). 
 
The cellular internalization of AuNP was studied by exposing NPs to HeLa cells, 
followed by extensive washing to remove NPs adsorbed to the cell surface. AuNP uptake 
was quantified using inductively coupled plasma mass spectrometry (ICP-MS), with the 
mass of intracellular gold converted to the AuNP number using a previously reported 
method.7 As expected, all cationic AuNP featuring TTMA surface ligands enter cells in a 
significantly higher efficiency than that of neutral zwitterionic and anionic AuNP (Figure 
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4A). Interestingly, zwitterionic NPs with positive outmost layer charge (Au-SN) entered 
cells more efficiently than NPs with negative outmost layer charge (Au-NS), and anionic 
Au-COOH NPs, indicating the charge orientation of zwitterionic AuNP significantly 
affected NP internalization.  
 
Figure 2.3. Cytotoxicity evaluation of gold nanoparticles featuring different size and 
surface charge in the absence of serum. HeLa cells were treated with 25 nM NPs for 3 h 
in the absence of serum. Mean values ± standard deviation, N = 3. 
 
While there were no major surprises when looking at the functionality axis alone, 
parametric variation of charge and size generated unexpected interrelationships. For the 
cationic particles, increasing particle size from 2 nm to 6 nm increased uptake efficiency 
3-fold (Figure 2.4B), a trend consistent with Chan’s study of larger AuNPs.18 A 
completely opposite trend was observed for both zwitterionic particles (NS and SN) and 
anionic particles, where increasing the core size decreased uptake, with 2 nm AuNPs 
uptaken >10-fold more efficiently than their 6 nm counterparts. This distinctive size 
dependence indicates that both particle size and surface functionality need to be 
considered together when designing carriers for cellular delivery.  
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Figure 2.4. A) Cellular uptake of as-synthesized gold nanoparticles with different size 
and varied surface charge by HeLa cells after 3 h incubation in serum-free media. The 
amount of gold per cell was determined by ICP-MS. Number of gold nanoparticles inside 
cells was also indicated above the histogram bar. B) Size-dependent uptake trend of 
AuNP. The uptake efficiency of 4 and 6 nm NP was normalized to that of 2 nm NP 
featuring the same surface charge. Mean values ± standard deviation, N = 3. 
 
Having found the size and surface charge dependence of the cellular uptake of 
AuNP in the absence of serum, we investigated further the uptake of these NP in 
complete cell culture medium containing 10% FBS, with the aim of understanding the 
effects of serum on NP uptake. For this purpose, HeLa cells were treated with NPs for 3 h 
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or 24 h in the presence of 10% FBS. The treatment of NPs (25 nM) had negligible 
cytotoxicity, with all treated cells having >90% viability 24 h post-treatment (Figure 2.5).  
 
Figure 2.5. Cytotoxicity evaluation of gold nanoparticles featuring different size and 
surface charge. HeLa cells were treated with 25 nM NPs for 24 h A) in the presence of 
serum and B) in the absence of serum. Mean values ± standard deviation, N = 3. 
 
The cellular uptake efficiency of different NP was similarly quantified using ICP-
MS. As shown in Figure 2.6A, all NPs were internalized less efficiently in the presence 
of serum compared to that in serum-free medium after 3 h of treatment. Our results are 
similar to previous reports of multiple particles that showed decreased cellular uptake in 
the presence of serum, possibly due to the nonspecific binding of proteins to the cell 
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membrane, a competitive process that slows the uptake of NPs when serum proteins are 
present.7, 27  
 
Figure 2.6. Cellular uptake of sub-10 nm NPs in the presence of serum. HeLa cells were 
treated with 25 nM AuNP for A) 3 h or B) 24 h in culture medium containing 10% FBS. 
The cellular uptake efficiency was determined by ICP-MS, the number of gold 
nanoparticles inside cells was also indicated above the histogram bar. Mean values ± 
standard deviation, N = 3. 
 
Notably, similar size and charge-determined cellular uptake trends were still 
observed for both zwitterionic and anionic NPs in the presence and absence of serum, 
while cationic NPs exhibited a significantly different trend. With 4 nm Au-TTMA NPs 
showed higher cellular uptake efficiency than that of 2 and 6 nm NPs in the presence of 
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serum. In addition, the incubation of NPs with cells for 24 h showed similar size and 
charge-dependent cellular uptake, with enhanced number of NPs internalized to cells 
(Figure 2.6B). The different uptake trend of cationic NPs in the presence and absence of 
serum protein probably resulted from the distinct protein corona formation on the 
different sized particle surface, suggesting an indirect correlation between surface 
chemistry and biological response.28 
Figure 2.7. Uptake efficiency of A) Au-TTMA NP, B) Au-COOH NP, C) Au-SN NP, 
and D) Au-NS NP by HeLa cells in the absence or presence of sodium azide (NaN3, 10 
mM) and deoxy-glucose (DOG, 50 mM) at 4 °C or 37 °C after 3 h incubation in serum-
free media. The cellular uptake efficiency of NPs (25 nM) was normalized to cells 
without inhibition treatment. Mean values ± standard deviation, N = 3. ∗ p < 0.05, ∗ ∗ p < 
0.01 compared to each normalized control. 
 
The opposite trends in size dependencies for neutral and charged particle uptake 
strongly suggested different mechanisms may be involved for the internalization of these 
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NPs. Previous studies have shown that energy-dependent endocytosis is the predominant 
pathway for nanoparticle internalization, a process that can be suppressed through 
reduced temperature and ATP depletion.29, 30 Cooling cells to 4 °C only had minor effects 
on the uptake of any of the 2 nm particles (Figure 2.7, and Figure 2.8). For the cellular 
uptake of all NPs at reduced temperature, we observed strong size dependence. 2 nm 
TTMA particles internalized much more efficiently than that of 6 nm TTMA NPs. With 
zwitterionic and anionic particles, little change of uptake was observed for the 2 nm and 4 
nm NPs. The behavior of the 6 nm particles differed, however, with a modest decrease 
observed for the SN particle and a much larger decrease observed with the NS analog and 
COOH particles. Qualitatively similar results were observed with pre-treatment of cells 
with sodium azide (NaN3, 10 mM)/2-deoxyglucose (DOG 50 mM) to deplete ATP, 
followed by AuNP exposure at 4 °C or 37 °C for ATP-depleted cells. Significantly, none 
of the 2 nm particles showed substantially different uptake under any of the conditions, 
strongly suggesting a different pathway was involved in the uptake of 2 nm NPs. 
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Figure 2.8. Cellular uptake of as-synthesized gold nanoparticles with different sizes and 
varied surfaces by HeLa cells after 3 h incubation in serum-free media A) at 37 °C, B) at 
4 °C, C) at 37 °C in the presence of NaN3 (10 mM) and DOG (50 mM), and D) at 4 °C in 
the presence of NaN3 (10 mM) and DOG (50 mM). The amount of gold per cell was 
determined by ICP-MS. Number of gold nanoparticles inside cells was also indicated 
above the histogram bar. Mean values ± standard deviation, N = 3. 
 
We next pre-treated cells with dynasore, an effective inhibitor of dynamin-
dependent endocytosis.31 We found that dynasore pre-treatment significantly inhibited 
the internalization of all Au-TTMA NP and 6 nm zwitterionic AuNPs (Figure 2.9 and 
Table 2.3). A strong size dependence was also observed for anionic NPs, 2 nm Au-
COOH particles were less inhibited by dynasore than that of 6 nm NPs. These studies 
collectively show that TTMA particles and 2 nm Au-COOH particles are internalized 
through multiple endocytotic pathways, while dynamin-mediated endocytosis is the only 
operative endocytotic mechanism for zwitterionic and 6 nm anionic particles, a 
completely unexpected outcome.    
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Figure 2.9. Uptake efficiency of A) Au-TTMA NP, B) Au-COOH NP, C) Au-SN NP, 
and D) Au-NS NP by HeLa cells in the presence of different endocytosis inhibitors. HeLa 
cells were treated with 25 nM NP for 3 h incubation in serum-free media. Mean values ± 
standard deviation, N = 3. ∗ p < 0.05, ∗ ∗ p < 0.01， ∗ ∗ ∗ p < 0.001 compared to each 
normalized control. 
 
We next compared the effects of endocytosis inhibitors on NP uptake. We first 
studied the effects of chlorpromazine (CPM) and sucrose, which inhibit clathrin-mediated 
endocytosis.32, 33, 34, 35, 36 As shown in Figure 2.9, CPM (28 nM) and sucrose (450 mM) 
pre-treatments significantly inhibited the internalization of all TTMA-coated AuNPs. 
However, negligible inhibition effect was observed for zwitterionic and anionic AuNP 
with similar CPM and sucrose pre-treatment, with no dependence on NP size, but with 
the exception that modest inhibition effect was observed for 2 nm Au-COOH NPs with 
CPM treatment. 
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Figure 2.10. Cytotoxicity evaluation of uptake inhibitors used in the study. HeLa cells 
were treated with NaN3 (10 mM)/DOG (50 mM), CPM (28 nM), sucrose (450 mM), 
dynasore (80 μM), nystatin (180 nM), or methyl-β-cyclodextrin (10 mM) for 3 h in the 
absence of serum, followed by cell viability assay. No obvious toxicity observed 
compared to normalized untreated control cells. Mean values ± standard deviation, N = 3. 
 
Finally, we studied the uptake difference of AuNP in the presence of cholesterol 
depletion agents that inhibit lipid raft-mediated uptake, in particular both membrane 
fusion processes and caveolae-dependent endocytosis.20, 37, 38, 39 The pre-treatment of 
cells with nystatin or methyl-β-cyclodextrin (MβCD) dramatically reduced uptake of all 
particles, including the 2 nm and 4 nm zwitterionic NPs that were unresponsive to other 
inhibitors (Figure 2.9 and Table 2.3). To exclude the possibility that these inhibitors may 
have interfered with the uptake of particles by inducing toxicity to cells, we measured the 
viability of HeLa cells treated with inhibitors for 3 h, and have not found obvious toxicity 
(Figure 2.10). 
Taken together, it is clear that the interplay of particle size and coverage plays a 
complex role in determining NP uptake. With cationic particles, multiple endocytic 
pathways, including clathrin- and caveolae/lipid raft-mediated endocytosis were observed 
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(Table 2.3 and Scheme 2.1). The zwitterionic NPs provided more specific mechanisms of 
uptake, with membrane fusion being the predominant mechanism for 2 nm and 4 nm 
zwitterionic NPs. In contrast, 6 nm zwitterionic NP were prone to enter cells through 
caveolae/lipid raft-mediated uptake, indicating a significant size-induced switching of the 
internalization mechanisms of NPs. Interestingly, 2 and 4 nm anionic particles displayed 
a similar multiple endocytic pathways to that of same sized cationic particles, while 6 nm 
anionic particles were internalized in caveolae/lipid raft-mediated pathway. 
Table 2.3. Summary of uptake inhibition of NP in presence of endocytic 
inhibitors.  +p < 0.05, ++p < 0.01, +++p < 0.001 through unpaired t-test. - no 
significant inhibition. 
 
A key feature of our study is the importance of surface coverage in determining 
cell uptake efficiency and mechanism. The distinct energy-independent cellular uptake of 
2 nm and 4 nm zwitterionic is consistent with the previous report by Alexander-Katz et al. 
that for small size NP (diameters ≤ 4 nm),40 the monolayer contains a large amount of 
free volume that maximizes the ligand fluctuations and minimizes the energy barrier to 
“snorkeling”, facilitating the energy-independent membrane fusion process for NPs to 
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enter cells. The 6 nm zwitterionic and anionic NPs are above the size threshold for 
membrane fusion so these NPs mainly enter cells via dynamin-dependent endocytosis 
pathway.  
 
Scheme 2.1. Interplay of size and surface functionality on the cellular uptake pathway of 
AuNP. 
 
2.3. Conclusions 
In summary, we have shown that there is a strong interrelationship between NP 
size and surface functionality on the cellular uptake of sub-10 nm gold nanoparticles. We 
have found that relatively small changes of NP core size were sufficient to induce 
dramatic changes in NP internalization efficiency and mechanism. These studies 
demonstrate that variation of particle size and coverage can be used synergistically to 
control cell uptake processes, an important design tool for bionanotechnology 
applications.  
2.4. Experimental Section 
Cell culture: HeLa cells were purchased from American Type Culture Collection 
(ATCC, Manassas, VA) and maintained in Low-glucose Dulbecco's modified Eagle's 
 45 
medium (DMEM) with 10% fetal bovine serum (FBS) and 1% antibiotic (100 U/mL 
penicillin and 100 μg/mL streptomycin). And the cells were cultured at 37 °C under a 
humidified atmosphere of 5% CO2.  
Synthesis of nanoparticle: The AuNP used in this study were synthesized by the 
Brust-Schiffrin two-phase method25 and Miyake’s heat-induced size evolution of gold 
nanoparticles,26 and were post-functionalized using the Murray place exchange 
reaction.41 Briefly, 2 nm dodecanethiol-protected gold nanoparticles (Au-DT NP) were 
heated to 154 °C at the heating rate of 2 °C /min and held for 30 min at 165 °C to obtain 
4 nm Au Au-DT NP. To obtain 6 nm Au-DT NP, 2 nm Au-DT NP were heated to 165 °C 
at the heating rate of 1 °C /min and held for 60 min at 165 °C. The zwitterionic,42  
cationic,43 and anionic ligands44 were synthesized according to our previous reports. Take 
2 nm Au-TTMA NP as an example, nanoparticles were prepared by conventional place-
exchange reaction of 2 nm sized 1-DT protected gold nanoparticles (Au_C12) with 
TTMA ligand. In a typical reaction, 10 mg of Au_C12 was dissolved in 10 mL distilled 
DCM and purged with argon for 10 min. Subsequently, 50 mg of TTMA ligand in 2.5 
mL of methanol was added to the nanoparticle solution. The reaction mixture was 
allowed to stirrer for 2 days followed by removal of solvent mixture. The resulting black 
colored residue was then washed with a mixture of hexanes (90%) and DCM (10%) for 
five times to remove 1-DT and excess ligands. This Au-TTMA NP nanoparticle residue 
was dissolved in distilled water and purified by dialysis with skin membrane (10,000 
MWCO) in distilled water for 3 days. Finally, molecular cut off filtration (10,000 
MWCO for five times) were performed. LDI-MS were used to ensure the high purity of 
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Au-TTMA NP nanoparticles. All other zwitterionic, cationic and anionic functionalized 
gold nanoparticles were synthesized using the same method. 
Characterization of as-prepared Au NPs: The morphology and core size of the 
AuNP was measured using a Tecnai G2 12 Transmission Electron Microscope (TEM, 
Philips, Netherlands) with 120 kV accelerating voltage. They were also characterized by 
laser-desorption/ionization mass spectrometry (Bruker Daltonics, Bremen, Germany) to 
confirm the zwitterionic, cationic and anionic coating. Optical absorption spectra were 
measured with a SpectraMax M5 (25 °C, Molecular Devices, USA). Zeta potential and 
hydrodynamic diameter of all twelve AuNPs were determined by a Zetasizer Nano ZS 
(25 °C, Malvern, England).  
Ligand coverage on NPs: Ligand coverage on each NP was determined 
according to a previous report.45 Briefly, 1.2, 0.5, and 0.3 µM of each 2 nm, 4 nm and 6 
nm AuNP was digested in 13 mg/mL I2 to cleave the ligands from the gold cores. The 
sample was sonicated for 30 minutes before being vortexed for another 30 minutes to 
ensure complete ligand cleavage. Then the supernatant was removed after centrifuged at 
14000 rpm for 30 minutes to separate the gold from the ligands. Free ligand served as the 
internal standard and different free ligand concentrations were prepared to build the 
calibration curve. Different matrixes were chosen for different NPs (TTMA: α-CHCA(α-
Cyano-4-hydroxycinnamic acid), SN/NS: DHB(2,5-Dihydroxybenzoic acid), COOH: 
9AA(9-Aminoacridine). Six spectra for each sample were collected and averaged to plot 
a calibration curve using the ratio between the signals obtained from free ligand and 
internal standard. Then the number of ligands around each NP was determined. 
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Nanoparticle uptake and inhibition studies: HeLa cells were seeded in a 48 
well plate at a density of ∼ 2 × 104 cells/well 24 h a day before experiment. At the day of 
incubation, cells were washed three time with phosphate buffered saline (PBS) and pre-
incubated with following endocytic inhibitors in serum free media for 1 h at 37 °C, 
methyl-β-cyclodextrin (10 mM), nystatin (180 nM), sodium azide (NaN3, 10 mM) with 2-
deoxyglucose (DOG, 50 mM), dynasore (80 μM), chlorpromazine hydrochloride (28 nM), 
and sucrose (450 mM). All inhibitors were purchased from Sigma except for dynasore 
was obtained from Fisher Scientific, and the concentrations of the inhibitors were used 
according to previous reports.15, 30 After 1 h, nanoparticles were added at a concentration 
of 25 nM and incubated for another 3 h at 37 °C in the presence of the inhibitors. 
Untreated cells were used as negative control, and cells treated with only NPs in the 
absence of inhibitors were used as positive control.  After incubation, cells were washed 
five times with PBS buffer. Cell lysis buffer (250 μL per well) was used to lyse the cell, 
with the cell culture plate kept at room temperature on a vibrator for 30 min. In addition, 
a freeze/thaw cycle was also adopted to further facilitate the cell lysis process. After that, 
cells were digested with 0.5 mL of fresh aqua regia for 10 min. The digested samples 
were further processed for ICP-MS analysis to determine the intracellular amount of gold.  
Each cell uptake experiment was done in triplicate, and each replicate was measured 5 
times by ICP-MS. 
Temperature and energy dependent pathways study: HeLa cells were seeded 
in a 48 well plate at a density of 2 × 104 cells/well a day before experiment. At the day of 
incubation, cells were washed three times with PBS buffer and pre-treated with 10 mM 
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NaN3 and 50 mM DOG at 4 °C for 1 hour, then HeLa cell were incubated with 25 nM Au 
NPs in the presence of NaN3/ DOG at 4 °C for another 3 hours.  
Sample preparation for ICP-MS and ICP-MS measurements: For the 
quantitative determination of Au content in the cellular uptake study, the cell lysates were 
digested with 0.5 mL fresh aqua regia composed of hydrochloric acid and nitric acid (3:1, 
v/v) (highly corrosive and must be used with extreme caution!) for 10 min.15, 46 Then 
each digested sample was diluted to 10 mL with de-ionized water. A series of gold 
standard solutions (20, 10, 5, 2, 1, 0.5, 0.2, and 0 ppb) were prepared at the same time. 
Each gold standard solution also contained 5% aqua regia. The gold standard solutions 
and cellular uptake sample solutions were measured on a Perkin-Elmer NexION 300X 
ICP mass spectrometer. 
Particle uptake efficiency (%) was calculated based on the following equation:  
Uptake efficiency (%) = (Number of NPs taken up by cells / Number of NPs 
incubated with cells) × 100 % 
And inhibition efficiency (%) was calculated by the following equation: Inhibition 
(%) = (Number of NP uptake in the presence of inhibitors / Number of NP uptake in the 
absence of inhibitors) × 100 % 
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CHAPTER 3 
CHEMICALLY ENGINEERED NANOPARTICLE-PROTEIN INTERFACE FOR 
REAL TIME CELLULAR OXIDATIVE STRESS MONITORING  
 
3.1. Introduction 
Hydrogen peroxide is a product of cellular respiration and is one of the most 
important reactive oxygen species endogenously generated by cells. 1  H2O2 plays 
fundamental roles in multiple physiological and pathological processes, with the 
controlled generation of H2O2 essential to maintaining homeostasis and hence cell 
survival.2 An overproduction of H2O2 results in oxidative stress that causes a range of 
diseases, including neurodegeneration,3 diabetes,4 and cancer.5 The importance of H2O2 
in biological processes necessitates the development of real-time sensing platforms for 
H2O2. Recently, fluorescent probes have been designed for H2O2 sensing, including small 
molecule fluorescent sensors,6 synthetic cell-penetrating peptides,7 genetically encoded 
fluorescent proteins,8 and nanozymes.9 However, the transient nature of ROS and the 
similarity of H2O2 with other ROS in terms of size and oxidative properties make 
peroxide sensing challenging. 
Hybrid nanomaterials integrating synthetic nanomaterials with biomolecules 
including proteins and nucleic acids are important tools for chemical and biosensing.10 
These systems incorporate key elements of biomolecular function with the unique 
physical structural attributes of nanomaterials.11 A substantial body of research exists on 
nucleic acid and peptide-functionalized nanomaterials, with protein-based systems 
rapidly emerging.12 These systems generally use native proteins for sensing applications, 
providing recognition elements (e.g., antibodies) as well as enzymatic function. Genetic 
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engineering of proteins provides a tool for creating NP-protein sensors with improved 
sensing selectivity and stability,13 however the complicated genetic fusion process and 
limited functional group options for proteins provide limitations to this approach.  
 
Scheme 3.1. Chemically engineered AuNP/PB-GFP interface for H2O2 sensing. A) 
Schematic illustrating the interfacing of AuNP-Gal with PB-GFP, and phorbol 12-
myristate-13-acetate (PMA) stimulated in situ H2O2 generation modulated GFP release 
from the AuNP/PB-GFP interface. B) Reaction mechanism of PB-GFP with H2O2 
catalyzed bioorthogonal PB cleavage. 
 
Chemical modification of proteins is an appealing alternative for endowing 
proteins with useful non-natural functionality and tunable properties.14 We reasoned that 
integrating the strategies of chemically modified proteins with nanoparticle surface 
engineering would yield hybrid nanomaterials with synergetic functionality. We report 
here the creation of H2O2-responsive NP-protein conjugates and their ability to 
selectively monitor endogenous H2O2 production in live cells. In this study, we modify 
green fluorescent protein (GFP) with boronate functionality at the primary amine of 
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lysine residues to provide a family of phenylboronate-functionalized GFPs (PB-GFPs). 
These proteins react with galactose-functionalized gold nanoparticles (AuNP-Gal) via 
boronate ester formation (Scheme 3.1). By tuning the extent of boronate modification of 
GFP through convenient chemical modifications, we demonstrate that the conjugation of 
PB-GFP with AuNP-Gal quenches the fluorescence of GFP depending on the number of 
boronate moieties conjugated to GFP. The PB-GFP/AuNP-Gal functionalization is 
peroxide-responsive: H2O2 catalyzes the bioorthogonal oxidation of boronate.14, 1a This 
oxidation disassembles the complex with concomitant restoration of GFP fluorescence 
(Scheme 3.1), providing selective GFP-based on-off H2O2 detection for real time and in 
situ cellular oxidative stress monitoring.  
3.2. Results and Discussion 
Boronate-functionalized GFP was prepared through the reaction of GFP with 4-
nitrophenyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonate (NBC) at 
different molar ratios. The number of phenylboronic acid (PB) conjugated to GFP was 
determined using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) 
mass spectroscopy (Figure 3.1).  
 
Figure 3.1. MALDI-TOF mass spectra of GFP and PB-modified GFP. 
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In this study, GFP conjugated with 5, 9, and 20 PB per protein molecule, 
designated as PB5-GFP, PB9-GFP, and PB20-GFP, respectively, were complexed with 
gold nanoparticles (2 nm core) functionalized with galactose ligands (AuNP-Gal) that 
were prepared through the place-exchange reaction of 1-pentanethiol protected gold 
nanoparticles (AuNP-C5) and galactose ligands.15 The AuNPs were characterized using 
transmission electron microscopy (TEM) and dynamic light scattering (DLS) analysis 
(Figure 3.2). In addition, GFP without PB conjugation (GFP) was used as a negative 
control to evaluate the effect of PB conjugation on enhancing protein-NP interaction.  
 
Figure 3.2. Characterizations of AuNP-Gal. A) TEM image of AuNP-Gal. B) Dynamic 
light scattering (DLS) diameter of AuNP-Gal (9.6 ± 1.2 nm, recorded in 5 mM phosphate 
buffer at pH 7.4 at a concentration of 1µM). C) Zeta-potential of AuNP-Gal (20.2 ± 2.5 
mV, recorded in 5 mM phosphate buffer at pH 7.4 at a concentration of 1 µM). 
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Figure 3.3. Fluorescence titration of PB-GFP with AuNP-Gal. 100 nM protein was 
mixed with increased amounts of AuNP-Gal in PBS, and after incubation for 15 min, the 
fluorescence intensity of GFP was recorded. GFP fluorescence (λex = 475 nm, λem = 510 
nm) in the presence of AuNP-Gal was normalized to that without AuNP-Gal addition. 
Each titration experiment was performed in three replicates. The red solid lines represent 
the best curve fitting using the previously reported method.16 
 
Table 3.1. Binding constants for the AuNP-Gal/PB-GFP complexes. 
 
 
The attachment between AuNP-Gal and PB-GFP was quantified by titrating GFP 
with AuNP and measuring the GFP fluorescence intensity change. The formation of a 
stable AuNP/PB-GFP interface efficiently quenches GFP fluorescence, providing 
straightforward observation of binding. As shown in Figure 3.3, the fluorescence of GFP 
solution (100 nM protein in PBS) shows little change with the addition of AuNP, 
indicating little binding between GFP and AuNP, in the presence of high concentration of 
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salt (137 mM NaCl). In contrast, PB-GFP fluorescence was quenched with the addition 
of AuNP, depending on the number of PB units conjugated to GFP and the amount of 
AuNP added to PB-GFP. For example, PB20-GFP fluorescence was quenched up to 90% 
at a NP to protein ratio of 0.2, while 18% and 70% GFP emission quenching was 
observed for PB5-GFP and PB9-GFP respectively under the same conditions. This 
enhanced quenching indicates PB20-GFP protein has a stronger binding affinity with 
AuNP than that of PB5-GFP and PB9-GFP. The binding constants for AuNP-Gal and 
PB20-GFP (2.0 ×108 M-1) are substantially higher than PB5-GFP (8.6 ×107 M-1) and 
PB9-GFP (6.6 ×107 M-1), as determined by the GFP fluorescence titration curve (Table 
3.1).16  
 
Figure 3.4. MALDI-TOF mass spectra of GFP, PB20-GFP before and after H2O2 
treatment. 30 µM PB20-GFP was treated with 30 mM H2O2 for MALDI-TOF analysis. 
 
It has been previously demonstrated that PB modified proteins are ROS-
responsive, as hydrogen peroxide can cleave the boronate from the conjugated proteins 
through a bioorthogonal oxidization reaction.14, 1a We confirmed the ROS-responsive 
nature of PB-GFP by treating PB20-GFP protein with H2O2, and characterizing PB 
cleavage using MALDI-TOF. As shown in Figure 3.4, MALDI-TOF analysis indicated 
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that the treatment of PB20-GFP (30 µM protein) with 30 mM H2O2 resulted in a loss of 
fourteen PB groups from PB20-GFP.  
 
Figure 3.5. Fluorescence intensity of PB20-GFP, and AuNP-Gal/PB20-GFP complexes 
before and after addition of H2O2. The AuNP-Gal/PB20-GFP conjugates were prepared 
by incubating PB20-GFP (100 nM) with a fixed PB20-GFP to AuNP-Gal ratio (4:1) for 
15 min. All GFP fluorescence values were presented relative to the PB20-GFP control. 
Error bar represents the standard deviation of three independent studies. Photograph 
showing fluorescence of PB20-GFP, AuNP-Gal/PB20-GFP complexes, and AuNP-
Gal/PB20-GFP complexes upon addition of H2O2 under ultraviolet light. 
 
 
Figure 3.6. Time course of PB20-GFP fluorescence response of AuNP-Gal/PB20-GFP 
(100 nM of PB20-GFP) complex treated with 1 mM H2O2. The fluorescence was 
presented relative to the PB20-GFP controls. 
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Figure 3.7. H2O2 concentration-dependent and selective modulation of the AuNP-
Gal/PB20-GFP interface. A) The fluorescence response of AuNP-Gal/PB20-GFP (100 
nM PB20-GFP) upon the addition of increasing concentrations of H2O2 in PBS 
containing 10% FBS. The fluorescence response was presented relative to the PB20-GFP 
control. B) Time-dependent fluorescence response of AuNP-Gal/PB20-GFP (100 nM 
PB20-GFP) upon addition of H2O2 (50 μM) or other ROS (100 μM) as indicated in PBS 
containing 10% FBS. Catalase (0.5 mg/mL) was added to verify the role of H2O2 in 
modulating AuNP/PB20-GFP interface. The fluorescence response was presented relative 
to the AuNP-Gal/PB20-GFP controls. 
 
The disassembly of the AuNP/PB-GFP by H2O2 was then followed using 
fluorescence spectroscopy. As shown in Figure 3.5, the attachment of AuNP (25 nM) to 
PB20-GFP (100 nM protein in PBS) quenched GFP fluorescence by 90%. Treatment of 
the complex with 1 mM H2O2 for 30 min resulted in essentially complete restoration of 
GFP fluorescence. As shown in Figure 3.6, the fluorescence of AuNP/PB20-GFP 
complex (100 nM GFP and 25 nM AuNP-Gal) increased shortly after adding 1 mM H2O2, 
no further GFP fluorescence changed was observed after 25 minutes of incubation, 
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indicating PB20-GFP protein was completely released from AuNP. The fast and dynamic 
process of the H2O2-regulated AuNP/PB20-GFP interface prompted us to study its 
potential application as an H2O2 assay.  
Novel sensing platforms that discriminate different types of ROS and are capable 
of real time monitoring of ROS generation are important to study the physiological role 
of ROS and develop new disease diagnostic tools.17 We evaluated the capability of the 
AuNP/PB20-GFP complex for sensitive and selective sensing of H2O2. As shown in 
Figure 3.7A, treatment of AuNP/PB20-GFP complex (100 nM PB20-GFP and 25 nM 
AuNP-Gal mixed in PBS containing 10% fetal bovine serum) with 20 µM H2O2, restored 
GFP fluorescence gradually within 2 h of incubation. Fast restoration of GFP 
fluorescence was observed for AuNP/ PB20-GFP complex treated with a higher 
concentration of H2O2. For example, 150 µM H2O2 restored GFP fluorescence to more 
than 90% after 40 minutes of incubation. The response of the AuNP/ PB20-GFP complex 
is very selective toward H2O2 (Figure 3.7B). The addition of a variety of biologically 
relevant ROS, including hypochlorite (ClO-), H2O2, tert-butyl hydroperoxide (TBHP), 
nitroxide radical (NO·), and H2O2 in the presence of catalase (which acts to degrade 
H2O2), generated no perceptible response from the complex. 
We next explored the utility of AuNP/PB20-GFP complex for real time 
monitoring of cellular oxidative stress. We first verified the use of the AuNP/PB20-GFP 
interface for H2O2 sensing in cell culture medium. To this end, human T lymphocyte 
Jurkat cells were spiked with different concentrations of H2O2, followed by an incubation 
with AuNP/PB20-GFP complex (100 nM PB20-GFP and 25 nM AuNP-Gal) and PB20-
GFP fluorescence measurement. As shown in Figure 3.8A, Jurkat cells alone had no 
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effect on disassembling the AuNP/PB20-GFP complex during the 2h of incubation, 
indicating the high stability of AuNP/PB20-GFP interface in biological media. The 
addition of 2.5 μM H2O2 resulted in a noticeable increase in fluorescence within 2h, 
while the GFP fluorescence was 2.5 times higher for AuNP/PB20-GFP complex spiked 
with 40 μM H2O2 (Figure 3.8A). Additionally, the GFP fluorescence is linearly correlated 
to the concentration of H2O2 spiked to the cell culture medium in the range of 2.5 to 40 
μM. 
 
Figure 3.8. Detection of H2O2 using the AuNP-Gal/PB20-GFP in cellular environment. 
A) Time-dependent fluorescence response of AuNP-Gal/PB20-GFP complex (100 nM of 
PB20-GFP) added to Jurkat cells spiked with different concentrations of H2O2. The 
fluorescence response was presented relative to the AuNP-Gal/PB20-GFP controls. B) 
The fluorescence response of AuNP-Gal/PB20-GFP (100 nM of PB20-GFP) incubated 
with Jurkat cells stimulated with PMA (0.5 µM), or incubated with catalase (0.5 mg/mL) 
and PMA (0.5 μM) simultaneously. All fluorescence values were presented relative to the 
AuNP-Gal/PB20-GFP controls. Error bar represents the standard deviation of three 
independent studies. 
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We next studied the capability of the AuNP/PB20-GFP interface to monitor 
endogenous H2O2 generated by Jurkat cells in the presence of the ROS stimulator, 
phorbol 12-myristate-13-acetate (PMA).7, 14 PMA treatment activates NAPDH oxidase 
and induces the generation of superoxide, which is converted to ROS species including 
H2O2.7 As shown in Figure 3.8B, Jurkat cells pretreated with 0.5 µM PMA before 
AuNP/PB20-GFP complex (100 nM PB20-GFP and 25 nM AuNP-Gal) incubation 
resulted in a significant enhancement of GFP fluorescence, compared to the cells without 
PMA stimulation. In addition, when 0.5 mg/mL catalase was simultaneously added to 
PMA-stimulated Jurkat cells, no GFP fluorescence enhancement was observed due to 
consumption of the generated peroxide. By calibrating the GFP fluorescence of PMA-
stimulated Jurkat cells to that of the AuNP/PB20-GFP complex in the presence of 
exogenous H2O2, we estimated that the PMA-stimulation generated H2O2 at a rate of 0.49 
nmol/104 cells/h, consistent with previous reports.7  
3.3. Conclusions 
In summary, we have co-engineered an NP-protein complex to provide an ROS-
responsive system for real time H2O2 sensing and monitoring of cellular oxidative stress. 
This complex was created and modulated by the complexation between galactose-
decorated gold nanoparticles and boronate modified protein. The assembled AuNP/PB-
GFP interface is highly stable under a physiological environment, with GFP fluorescence 
generated by H2O2, providing a dosimetric response. The responsiveness of this system 
demonstrates the utility of co-engineering for creating functional and responsive 
synthetic-biological hybrid nanomaterials, a strategy that can be applied to many 
biological and physiological challenges.  
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3.4. Experimental Section 
Synthesis of AuNP-Gal nanoparticle: 1-pentanethiol protected 2 nm gold 
nanoparticle (AuNP-C5) and galactose ligand were synthesized according to previous 
reports. AuNP-Gal was prepared through the place-exchange reaction between AuNP-C5 
and galactose ligand. Briefly, 40 mg of galactose ligand was added to a 3 mL CH2Cl2 
solution of 10 mg AuNP-C5.15 The reaction mixture was stirred for another 48 h at room 
temperature, followed by solvent evaporation in vacuo. The resulted residue was then 
washed extensively with a mixture of hexanes and DCM to remove 1-pentanethiol and 
excessive galactose ligand. The crude nanoparticle was then dialyzed against water for 3 
days using SnakeSkinTM Dialysis Tubing (Thermo Scientific, 10,000 MWCO). Finally, 
molecular cut off filtration (10,000 MWCO) was performed 5 times to ensure the purity 
and to concentrate the galactose-functionalized gold nanoparticles.   
Green fluorescent protein (GFP) modification: Recombinant GFP was 
expressed according to our previous report.12 PB-GFP was prepared by reacting native 
GFP with 4-nitrophenyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonate 
(NBC) at different ratios.14 Briefly, 0.7 mg GFP was dissolved in 0.1 M NaHCO3 buffer 
solution (pH = 8.5) at a protein concentration of 1 mg/mL. To above solution, 150 µL 
DMSO solution containing 0.25, 0.5, or 1 mg NBC was added to prepare PB5-GFP, PB9-
GFP, and PB20-GFP, respectively. The reaction mixtures were then stirred at room 
temperature for additional 10 h, followed by ultrafiltration purification using Amicon® 
Ultra Centrifugal Filters (MWCO = 10,000, Millipore, MA). Matrix assisted laser 
desorption/ionization mass spectrometry (MALDI-MS) was used to characterize 
modified GFP. A saturated sinapinic acid stock solution was prepared in 50% 
acetonitrile, 50% H2O, and 0.1% TFA. An equal volume of 1 mM PB-GFP solution was 
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added to the matrix stock solution. 2.5 μL of this mixture was spotted on the sample 
carrier, and MALDI-MS analysis was performed on a Bruker Autoflex III mass 
spectrometer.  
PB-GFP fluorescence titration with AuNP-Gal: PB-GFP (100 nM) was titrated 
with increased concentration of AuNP-Gal, ranging from 0 to 90 nM. GFP fluorescence 
(λex = 475 nm, λem = 510 nm) in the presence of AuNP-Gal was normalized to that 
without AuNP-Gal addition. Nonlinear least-squares curve fitting analysis was used to 
estimate the binding constant (Ka) between PB-GFP and AuNP-Gal according to our 
previous reports.16 
H2O2-modulated AuNP/PB20-GFP fluorescence response: AuNP-Gal/PB20-
GFP complexes was incubated with different concentrations of H2O2, ranging from 0 to 
150 μM at 37 °C. These AuNP-Gal/PB20-GFP conjugates were pre-prepared in a fixed 
PB20-GFP concentration (100 nM) and PB20-GFP to NP ratio (4 : 1) in 10% FBS 
containing PBS for 15 minutes. PB20-GFP fluorescence was monitored for 120 minutes, 
and the fluorescence values were presented relative to the PB20-GFP control. All 
experiments were performed independently at least three times. 
Selective H2O2 assay using AuNP/PB20-GFP interface: AuNP-Gal/PB20-GFP 
complexes (pre-prepared in a fixed PB20-GFP concentration (100 nM) and PB20-GFP to 
NP molar ratio (4 : 1) in 10% FBS containing PBS for 15 minutes) was treated with 50 
μM H2O2 or other ROS (final concentration was 100 μM) at 37 °C, the PB20-GFP 
fluorescence was monitored every 5 minutes for 120 minutes, and presented relative to 
the AuNP-Gal/PB20-GFP controls. ROS were generated as follows: hydrogen peroxide 
(H2O2), tert-butyl hydroperoxide (TBHP) and hypochlorite (ClO-) were introduced from 
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commercially available aqueous solution, nitric oxide (NO•) was generated from PROLI 
NONOate. The catalase concentration, when present, was 0.5 mg/mL. All experiments 
were performed in triplicate. 
Cell Culture: Jurkat cells were purchased from ATCC. Cells were maintained in 
RPMI-1640 medium (Life technologies), supplemented with 10% FBS, and 1% 
antibiotics (Cellgro). Cells were cultured in a humidified atmosphere containing 5% CO2 
at 37 °C and sub-cultured every four days. 
Cellular assays using AuNP/PB20-GFP: Jurkat cells (1×104 cells in 100 μL 
culture medium) were split into black 96-well plates, to which AuNP-Gal/PB20-GFP 
complexes (pre-prepared in a fixed PB20-GFP concentration (100 nM) and PB20-GFP to 
NP molar ratio (4 : 1) in 10% FBS containing PBS for 15 minutes) were added. For the 
spiked H2O2 assay, H2O2 with concentration increased from 0 to 40 μM was added to 
above cells, followed by GFP fluorescence monitoring every 10 minutes for 120 minutes 
at 37 °C. For real time cellular oxidative stress study, Jurkat cells were treated with either 
PMA (0.5 μM) or a combination of PMA (0.5 μM) and catalase (0.5 mg/mL), followed 
by the addition of AuNP-Gal/PB20-GFP complexes. The fluorescence restoration of GFP 
was similary recorded within 120 minutes, and presented relative to the AuNP-Gal/PB20-
GFP controls. All experiments were performed independently at least three times.  
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CHAPTER 4 
DIRECT CYTOSOLIC DELIVERY OF SIRNA USING NANOPARTICLE-
STABILIZED NANOCAPSULES  
 
4.1. Introduction 
RNA interference (RNAi) is an endogenous pathway that silences gene 
expression at a post-translational level. The predominant strategy for RNAi uses small 
interfering RNA (siRNA) to target and cleave complementary mRNA, with concomitant 
inhibition of protein translation.1 Since the discovery of RNAi by Fire et al.2 and siRNA 
by Tuschl et al., 3 the application of RNAi to knock down the expression of tumor-
specific proteins or anti-apoptotic pathways has emerged as a novel therapeutic approach 
for cancer treatments.4 siRNA is a double-strand RNA with a 21-23 base pair length, and 
hence possesses a high molecular weight and multiple negative charges. 5  These 
physicochemical characteristics prevent passive diffusion across the membrane of most 
cell types for RNAi,6 thus necessitating vectors for delivery of siRNA into cytosol, where 
the incorporation of siRNA into RNAi machinery occurs.7 
Recently, nanocarriers have been developed for siRNA delivery, including 
polymers, 8 liposomes,9 and inorganic nanoparticles. 10  These siRNA vehicles generally 
enter cells through endocytic pathways, and are prone to entrapment within subcellular 
compartments.11 This entrapment requires an increased dosage of siRNA, thus increasing 
the possibility of off-target effects.12 Polyamine polymers and dendrimers can facilitate 
the escape of siRNA from endosomes 13  by taking advantage of the “proton sponge 
effect”. 14 These highly cationic vehicles are, however, associated with cytotoxicity. 15 
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Therefore, delivery of siRNA into the cytosol remains a key challenge for the application 
of RNAi,16 with direct cytosolic delivery providing the optimal outcome. 
In this study, we demonstrate direct cytosolic delivery of siRNA using 
nanoparticle-stabilized nanocapsules (NPSCs). The stability of NPSC relies on the 
supramolecular guanidine-carboxylate interactions between the arginine-functionalized 
gold nanoparticles (Arg-AuNP) of the shell and the hydrophobic fatty acid “oil” 
components in the core (Figure 4.1a). This method produces nanocapsules capable of 
effective delivery of both small molecules 17  and proteins. 18  We hypothesized that 
electrostatic self-assembly of Arg-AuNP and siRNA on the surface of the oil droplet 
would generate stable nanocapsules for siRNA delivery applications.  
We report herein the preparation of a NPSC/siRNA which provides cytosolic 
delivery of siRNA, as revealed through still and video microscopy of fluorescently 
labeled siRNA delivery. Moreover, we demonstrate that this cytosolic siRNA delivery 
process is mediated by direct fusion between the NPSCs/siRNA complex and the cell 
plasma membrane. The cytosolic delivery of siRNA resulted in highly efficient (90%) 
knockdown of a destabilized green fluorescence protein (deGFP) in deGFP-HEK293 
cells. Moreover, the delivery of siRNA targeting polo-like kinase 1(siPLK1) silenced 
PLK1 expression in cancer cells, thus resulting in pronounced toxicity. The effective 
siRNA gene silencing using NPSC suggests the high potency of NPSC-facilitated direct 
cytosolic siRNA delivery as a platform to knock down targeted genes for disease 
treatment. 
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Figure 4.1. Preparation and characterization of NPSC/siRNA. a) NPSC/siRNA 
components and schematic presentation of NPSC mediated cytosolic siRNA delivery. b) 
Gel electrophoresis study of NPSC/siRNA complexation at molar ratios ranging from 1.1 
× 10-4 to 11 × 10-4. c) TEM images of NPSC/siRNA. d) Protection of siRNA from RNase 
A digestion as evaluated by electrophoresis. 5 pmol of siRNA alone or complexed with 
NPSC were incubated with 7, 14, and 35 mU RNase A at 37 °C for indicated times. 
 
4.2. Results and Discussion 
NPSCs were prepared according to our previous reports.18 Briefly, a template 
emulsion was prepared by homogenizing Arg-AuNP with linoleic acid in 5 mM 
phosphate buffer (pH = 7.4). The template emulsion was transferred to Arg-AuNP 
solution and incubated for additional 10 minutes to afford stabilized NPSCs. The NPSCs 
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was then mixed with siRNA at different molar ratios and incubated at room temperature 
for 15 minutes, followed by a gel electrophoresis assay and Ribogreen assay to measure 
siRNA encapsulation. As shown in Figure 4.1b, with the NPSCs to siRNA molar ratio 
increased from 1.1 × 10-4 to 11 × 10-4, the migration of siRNA on the gel was gradually 
retarded. The binding at a molar ratio of 5.5 × 10-4 completely retarded siRNA from 
migration, with (91 ± 2) % of siRNA encapsulation, as determined by Ribogreen assay. 
This optimized NPSCs to siRNA binding ratio was fixed for all subsequent intracellular 
delivery experiment. The encapsulation of siRNA had negligible effect on the 
morphology of NPSCs, as revealed by transmission electron microscopy (TEM, Figure 
4.1c). Dynamic light scattering (DLS) indicated NPSCs and NPSCs/siRNA formed 
nanoparticles with size at 149 ± 5 nm and 179 ± 8 nm in diameter, respectively (Table 
4.1). The slightly increased size of NPSCs/siRNA compared to that of NPSCs is 
consistent with swelling arising from the encapsulation of siRNA onto the NPSCs surface. 
Additionally, the zeta potential of NPSCs was made more negative from -25.5 mV to -
39.4 mV for NPSCs/siRNA complex, thus confirming the successful encapsulation of 
siRNA into NPSCs. 
The encapsulation of siRNA into NPSCs efficiently protected siRNA against 
nuclease degradation, a prerequisite for the intracellular delivery of siRNA. As shown in 
Figure 4.1d, the treatment of free siRNA with Ribonuclease A (RNase A, 7 mU) for 1 h 
resulted in complete degradation of siRNA.19 However, significant amounts of siRNA 
were still detected after the treatment of NPSCs/siRNA complex even at a much higher 
RNase A amount (35 mU) and a longer incubation (2 h). Similarly, the NPSCs/siRNA 
complex efficiently protected siRNA against serum degradation (Figure 4.2). The 
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enhanced enzymatic stability of siRNA with NPSC encapsulation may be ascribed to 
steric protection and neutralization of siRNA charge, which together decreased the 
susceptibility of siRNA toward nuclease degradation. 
Table 4.1. DLS measurements of size (number average), polydisperse index 
and zeta potential of NPSC and NPSC/siRNA complex. 
 
 
 
Figure 4.2. Agarose gel electrophoresis assay of NPSC protected siRNA from 
degradation. a) NPSC protected siRNA from RNase A digestion. siRNA or NPSC/siRNA 
complex were incubated with indicated amount of RNase A for 1 and 2 h. b) Serum 
stability of NPSC/siRNA. siRNA or NPSC/siRNA complex were incubated with 10% 
FBS at 37 °C for indicated time before electrophoresis. 
 
 We prepared a NPSCs complex encapsulating fluorescently labeled siRNA (Cy3-
siRNA) with a scrambled sequence to evaluate delivery of siRNA.20 The cellular uptake 
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and subcellular localization of NPSCs/siRNA complex was then monitored using 
confocal laser scanning microscopy (CLSM). Significant intracellular accumulation of 
red fluorescence occurred when the cells were treated with the NPSCs/Cy3-siRNA 
complex (Figure 4.3a). Significantly, the Cy3 fluorescence was evenly distributed within 
whole cell, and had little overlap with the endosome/lysosome by using 
LysoTracker@Green counter-staining. The CLSM studies suggest that the NPSC/siRNA 
complex was able to transport siRNA directly into cytosol without endosome/lysosome 
entrapment that associated with polymer or lipid-based siRNA delivery vehicles.7 
NPSCs- mediated siRNA uptake is dependent on siRNA concentration. With the Cy3 
siRNA increased from 12 nM to 36 nM, the Cy3 fluorescence intensity increased up to 
ten-fold, and greater than 70% cells were Cy3 fluorescence positive, as measured by flow 
cytometry analysis (Figure 4.4).  
The siRNA uptake and trafficking dynamics of NPSCs/siRNA delivery was 
investigated using time-lapse fluorescence imaging of Cy3-siRNA (Figure 4.3b). With 
the addition of NPSCs/Cy3-siRNA complex into HeLa cells, the fluorescence images of 
cells post-transfection were immediately captured at 1 minute interval. Time-lapse 
imaging analysis revealed that cytosolic siRNA fluorescence could be recorded within 5 
minutes of exposure of NPSCs/siRNA complex to cells, and the siRNA fluorescence was 
saturated after 20 min. of incubation, thus demonstrating extraordinary fast and efficient 
siRNA delivery using NPSCs. The siRNA fluorescence was evenly distributed within 
whole cell cytosol further demonstrating that NPSCs-mediated siRNA delivery enter cells 
bypassing endo/lysosomes.21 
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Figure 4.3. Cytosolic delivery of Cy3-labeled siRNA into HeLa cells. a) Confocal 
microscopy images of HeLa cells after 1 hour treatment with 40 nM of NPSC/Cy3-
siRNA complex. siRNA are not colocalize with endolysosomes. Endosome/lysosome 
was stained with LysoTracker @Green. Scale bars: 20 μm. b) Live cell imaging of rapid 
Cy3-siRNA release into the cytosol of HeLa cell by NPSC. “0 min” label represents the 
starting point of release. Scale bars: 20 μm. c) FITC-dextran and NPSC/Cy3-siRNA were 
co-incubated with HeLa cells in the absence and presence of nystatin (100 μg/mL). d) 
Flow cytometry analysis of HeLa cells with NPSC/Cy3-siRNA treatment at 37 °C, or at 
4 °C, or with a pre-treatment of dynasore (80 μM). The error bars represent the standard 
deviations of three parallel measurements. 
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Figure 4.4. Cellular uptake study of NPSC/Cy3-siRNA complex. a) Representative flow 
cytometry plots of Cy3-siRNA positive HeLa cells. HeLa cells without NPSC/Cy3-
siRNA (up) and with 36 nM NPSC/Cy3-siRNA (bottom) treatment were harvested for 
flow cytometry analysis. b) siRNA dose- dependent cellular uptake. HeLa cells were 
treated with NPSC/Cy3-siRNA containing varied concentration of siRNA for 4 h. The 
error bars represent the standard deviations of three parallel measurements. 
 
In our previous study on protein delivery, we observed a similar even cytosolic 
distribution of GFP, thus prompting us to hypothesize that a membrane fusion process 
was operative.17 While there is circumstantial evidence of this mechanism, further 
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studies were performed to test this hypothesis. The efficiency of membrane fusion-
mediated uptake is dependent on the cholesterol level in cell membrane.22 To explore 
whether NPSCs delivered siRNA in a membrane-fusion pathway, HeLa cells were 
pretreated with nystatin (100 μg/mL), an inhibitor which has been used to deplete 
cholesterol from the plasma membrane,23 prior to siRNA transfection. Meanwhile, FITC-
labeled dextran, known to enter cells via endocytic pathways,24 was co-incubated with 
cells to exclude the potential effect of nystatin treatment on endocytosis. Nystatin has no 
effect on the stability of NPSC/siRNA complex, as revealed by the size of NPSC/siRNA 
complex in the presence and absence of nystatin (Figure 4.5).  
 
Figure 4.5. Hydrodynamic diameter of NPSC/siRNA complex before (179 ± 9 nm, red 
line) and after (179 ± 12 nm, green line) nystatin (100 μg/mL) incubation. The 
nanoparticle sizes were measured by DLS. 
 
The siRNA and FITC-dextran uptake was then monitored by CLSM imaging. As 
shown in Figure 4.3c, both dextran and NPSCs/siRNA efficiently enter HeLa cells in the 
absence of nystatin, with low co-localization observed between dextran and siRNA, 
confirming non-endocytic uptake of NPSC/siRNA complex. The treatment of nystain 
significantly blocked siRNA uptake, however, no uptake inhibition was observed for 
FITC-dextran. The siRNA uptake inhibition by nystatin treatment was further confirmed 
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and quantified by flow cytometry analysis (Figure 4.6). Nystatin pre-treatment 
significantly decreased the siRNA fluorescence intensity of HeLa cells, and the weak Cy3 
fluorescence could be ascribed to the nonspecific binding of NPSCs/siRNA complex on 
cell surface, as confirmed by z-stack CLSM imaging of NPSC/siRNA uptake (Figure 4.6). 
The above results indicated that nystain treatment did not block the endocytosis of FITC-
dextran, but inhibited the membrane fusion of siRNA by depleting cell membrane 
cholesterol. 
 
Figure 4.6. Cholesterol depletion significantly blocks siRNA uptake. a) CLSM images of 
HeLa cells treated with Cy3-labeled siRNA (40 nM siRNA complexed with NPSC) 
without (left) and with (right) a pre-treatment of nystatin (100 μg/mL). Scale bars: 20 μm. 
b) z-stacked CSLM images of HeLa cells treated with NPSC/Cy3-siRNA complex. The 
three dimensional cutout at the top of the image shows nanoparticles localize on the cell 
surface and have not penetrated into the cytosolic portion of the cell. Scale bar: 20 μm. c) 
Flow cytometry analysis of Cy3-labeled siRNA uptake in HeLa cells without (blue) or 
with (green) a pre-treatment of nystatin (100 μg/mL). The error bars represent the 
standard deviations of three parallel measurements. 
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We further investigated siRNA uptake efficiency by studying the uptake at 
reduced temperatures and by inhibiting dynamin. We pretreated HeLa cells at 4 °C for 30 
minutes before the exposure of NPSCs/Cy3-siRNA, and the siRNA uptake was 
quantified by flow cytometry analysis and compared to that at 37 °C. As shown in Figure 
4.3d, Cy3 fluorescence arising from siRNA uptake was significantly decreased for cells 
with pretreatment at 4 °C, similar to previous reports that the membrane fusion process is 
a temperature dependent process. 25  Meanwhile, the treatment of HeLa cells with 
dynasore (80 μM), an inhibitor of dynamin which regulates membrane fusion by 
expanding the fusion pores, 26 similarly reduced the cellular uptake of siRNA (Figure 
4.3d). Taken together, the above cellular uptake studies indicate that NPSCs facilitated 
cytosolic siRNA delivery is a cholesterol-dependent membrane fusion process.  
 
Figure 4.7. Viability of deGFP-HEK293 cells treated with NPSC/siRNA (red square) or 
Lipofectamine 2000/siRNA (black square) complexes. Scrambled siRNA was used to 
complex with NPSC or Lipofectamine 2000. The error bars represent the standard 
deviations of three parallel measurements. 
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Figure 4.8. NPSC/siRNA delivery silenced the deGFP expression of deGFP-HEK293 
cells. a) Confocal microscopy images of deGFP-HEK 293 cells without siRNA 
transfection (top left), with 60 nM of NPSC/siScr (top right), with 60 nM of 
NPSC/si_deGFP (bottom left) and with 60 nM of NPSC/si_deGFP with nystatin pre-
treatment (bottom right). Scale bars: 40 μm. b) Quantification of deGFP expression of 
deGFP-HEK 293 cells without treatment, with naked si_deGFP, NPSC/siScr, 
NPSC/si_deGFP, Lipofectamine 2000 (LPF2K)/si_deGFP, and NPSC/si_deGFP with 
nystatin pretreatment. 60 nM of si_deGFP or scrambled siRNA was used for transfection. 
The fluorescence intensity was measured by flow cytometry analysis and normalized to 
cells without treatment. The error bars represent the standard deviations of three parallel 
measurements.  
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We next evaluated the biocompatibility of the NPSCs/siRNA delivery platform by 
treating destabilized GFP-expressing HEK293 cells with varied concentrations of 
NPSCs/siRNA complexes, followed by cell viability assay. With siRNA concentrations 
(complexed with NPSCs) from 10 nM to 60 nM the cells retained viabilities greater than 
80% (Figure 4.7), with the biocompatibility of NPSCs comparable to that of a 
commercial gene transfection reagent, Lipofectamine 2000. 
         
Figure 4.9. deGFP expression profiles of deGFP-expressing HEK 293 cells with 
different siRNA treatments. a) Flow cytometry histograms of deGFP-HEK293 cells 
treated with NPSC/si_deGFP and controls. 60 nM of si_deGFP or scrambled siRNA was 
mixed with NPSCs for transfection. b) Quantitative analysis of deGFP expression in 
deGFP-HEK293 cells treated with increasing concentrations of NPSC/si_deGFP 
complexes. The error bars represent the standard deviations of three parallel 
measurements. 
 
Having demonstrated the efficient yet safe cytosolic delivery of siRNA using 
NPSCs, we next investigated the efficacy of the NPSCs-facilitated siRNA delivery to 
knock down targeted genes. As many disease-related proteins have short half-lives inside 
cells, an efficient siRNA delivery to silence the gene having a short half-life would have 
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a high therapeutic index. 27 In this study, destabilized GFP (deGFP) with a half-life of 
around 2 h was chosen as a testbed target gene.  
Stable-expressing deGFP-HEK293 cells were treated with NPSCs/siRNA 
complex targeting deGFP (NPSC/si_deGFP) or a scrambled siRNA (NPSCs/siScr), and 
the deGFP expression profiles were monitored by CLSM imaging and flow cytometry 
analysis. As shown in Figure 4.8a, only very faint fluorescence signal was observed in 
the CLSM images when the cells were treated with NPSCs/si_deGFP complex, indicating 
the high efficiency of NPSC mediated deGFP knockdown. Flow cytometry analysis 
revealed that the NPSCs/siRNA complex treatment (with 60 nM of si_deGFP) silenced 
the deGFP expression down to a level below 10% of blank control (Figure 4.8b and 
Figure 4.9). This gene silencing efficiency is substantially superior to the commercial 
lipid-based gene transfection reagents Lipofectamine 2000 (LPF2K, Figure 4.8b) and 
RNAi Max (Figure 4.10).  
 
Figure 4.10. deGFP expression profiles of deGFP-expressing HEK 293 cells with 
different siRNA treatments. RNAi Max (RMax) was used as a positive control to 
compare the GFP silencing efficiency using NPSC. The normalized deGFP fluorescence 
intensity was measured by flow cytometry analysis and normalized to cells without 
treatment. The error bars represent the standard deviations of three parallel measurements. 
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Figure 4.11. Quantification of deGFP expression of deGFP-HEK 293 cells without 
treatment, with NPSC/si_deGFP, NPSC/si_deGFP with dynasore pretreatment (80 μM), 
and with only dynasore pretreatment (80 μM). 36 nM of si_deGFP was used for 
transfection. 
 
The NPSC/si_deGFP complex silenced deGFP genes in a siRNA concentration 
dependent manner. With siRNA concentration increased from 20 nM to 60 nM the 
deGFP expression was gradually suppressed from 90% down to 10% of blank controls 
(Figure 4.9). As expected, no gene silencing was observed when the cells were treated 
with either naked si_deGFP or an NPSC/siRNA complex with a scrambled sequence 
(Figure 4.8b). As NPSCs delivered siRNA via a membrane fusion pathway, we 
hypothesized that the pre-treatment of HEK cells with nystatin to deplete cholesterol 
could block siRNA uptake and gene silencing. The GFP gene knockdown efficiency of 
HEK cells with nystatin or dynasore pretreatment, followed by NPSC/side_GFP 
treatment, was significantly decreased, as indicated by the strong fluorescence in CLSM 
images (Figure 4.8a) and minor GFP gene knockdown in the flow cytometry analysis 
(Figure 4.8b and Figure 4.11). The GFP gene silencing results again confirmed that 
NPSC facilitated siRNA is a cholesterol-dependent membrane fusion process, and the 
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cytosolic siRNA delivery is superior to commercial reagents in terms of gene silencing 
efficiency. 
 
Figure 4.12. NPSC mediated siPLK1 delivery in MDA-MB-231 cells. a) Cell viability of 
MDA-MB-231 cells treated with NPSC/siPLK1 or scrambled siRNA (40 nM). For the 
Lipofectamine 2000 control, 40 nM of siPLK1 was complexed with LPF2000 according 
to manufacturer's instructions. b) Representative PLK1 protein expression of MDA-MB-
231 cells determined by Western blot analysis after incubation with 40 nM siPLK1 in 
NPSC/siPLK1 and controls. GAPDH expression was measured in all the samples to serve 
as an internal control. 
 
Finally, we investigated the delivery of therapeutic siRNA. Polo-like kinase 1 
(PLK1) was selected as a model therapeutic target. PLK1 is a key regulator of mitotic 
progression of cells, and is up-regulated in many types of cancer cells.28 Inhibition of 
PLK1 activity or the depletion of PLK1 protein can induce mitotic arrest and prevent 
tumor cell proliferation.29 Treatment of MDA-MB-231 cells with 40 nM NPSCs/siPLK1 
reduced cell viability to 30% whereas no change in viability was observed with naked or 
NPSC/siRNA scrambled controls (Figure 4.12a). Significantly, NPSCs/siPLK1 inhibited 
cell proliferation with a higher efficiency than that of LPF2000. Knockdown of 
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intracellular PLK1 protein was determined by western blot analysis. Essentially complete 
knockdown was observed when MDA-MB-231 cells were treated with NPSCs/siPLK1 
(40 nM siRNA) (Figure 4.12b), with protein expression decreased by about 95%, a 
significantly greater knockdown than LPF2000/siPLK1 complexes. 
4.3. Conclusions 
In summary, we have demonstrated that NPSCs/siRNA complexes provide a 
highly effective siRNA transfection strategy. Microscopy studies showed that these 
systems delivered siRNA directly to the cytosol, providing efficient utilization of the 
siRNA payload by avoiding endosomal sequestration. In addition, we proved that such a 
direct cytosolic siRNA delivery was a temperature-dependent membrane fusion process. 
Extremely efficient (>90% GFP gene silencing) and effective PLK1 silencing for cancer 
therapy was achieved with this vehicle, and was substantially better than commercial 
available systems. Taken together, NPSCs/siRNA complexes provide effective tools for 
in vitro applications, and promising platforms for biomedical delivery. 
4.4. Experimental Section 
NPSC and siRNA complexation and gel electrophoresis: The arginine-
functionalized AuNP (Arg-AuNP) and NPSC were synthesized according to our previous 
report. Briefly, 1 μL of linoleic acid was mixed with 500 μL of phosphate buffer (5 mM, 
pH = 7.4) containing 1 μM Arg-AuNP and agitated by an amalgamator at 5000 rpm for 
100 s to form emulsions. Then, 10 μL of the emulsion was added into 90 μL of 5 mM 
phosphate buffer containing 2.5 μM Arg-AuNP and incubated for 10 min. at room 
temperature to afford NPSC. To optimize the condition for siRNA encapsulation, 5 pmol 
siRNA was mixed with NPSC at different molar ratios (The concentration of NPSC was 
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calculated according to reported method) for 20 min., and then subject to electrophoresis 
on an agarose gel (0.8% w/v) for 30 min. at 120 mV in TAE buffer (40 mM Tris-HCl, 1% 
v/v acetic acid, 1 mM EDTA). To evaluate the protection of siRNA against RNase A 
digestion, 5 pmol of free siRNA or NPSC/siRNA complex was incubated with varied 
amount of RNase A at 37 °C. At the indicated times, the enzymatic reaction was stopped 
by adding sodium dodecyl sulfate to denature RNase A at 60 °C for 5 min. To above 
reaction mixture was added heparin solution, followed by another 10 min. incubation to 
displace siRNA from NPSC, the samples were then analyzed by electrophoresis on 
agarose gels (0.8% w/v). For NPSC/siRNA serum stability study, 5 pmol of 
NPSC/siRNA complex was incubated in 10 uL PB (5 mM, pH = 7.4) containing 10% 
FBS at 37 °C for 1 h and 2 h. The nucleases in FBS were denatured by adding 1 uL 50 
mM SDS solution, followed by an additional 5 min. of incubation at 60 °C. The siRNA 
was released from NPCS/siRNA complex by adding 1 uL of 50 mg/mL heparin solution. 
The above samples were then assayed by electrophoresis by using 0.8% agarose gel as 
we described above. 
Cell culture: HeLa cells and MDA-MB-231 cells were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). deGFP expressing HEK293 cells were 
a generous gift from Prof. Eben Alsberg (Case Western Reserve University). All cells 
were cultured at 37 °C under a humidified atmosphere of 5% CO2. Low-glucose 
Dulbecco’s modified Eagle’s medium (DMEM, 1.0 g/L glucose, for HeLa cells), and 
high-glucose DMEM (4.5g/L, for HEK293 cells and MDA-MB-231 cells) supplemented 
with 10% fetal bovine serum (FBS) and 1% antibiotic (100 U/mL penicillin and 100 
μg/mL streptomycin) was used for cell culture.  
 86 
Fluorescently labeled Cy3-siRNA delivery: For confocal laser scanning 
microscopy (CLSM) imaging of the cellular uptake of NPSC/siRNA complex, HeLa cells 
(2.0 × 105 cells) were seeded in a 35 mm glass bottom culture dish (MatTek, MA) a day 
before experiment. At the day of delivery, the culture medium was removed and replaced 
with Opti-MEM containing 40 nM NPSC/Cy3-siRNA, followed by another 2 h of 
incubation at 37 °C. After removing medium, the cells were washed three times with cold 
phosphate buffer saline (PBS) for fluorescence imaging under a Zeiss LSM 710 confocal 
microscope. For the time-lapse live cell imaging, 2.0 × 105 HeLa cells were cultured in 
the confocal dish 24 h prior to the experiment. Before the cell imaging, cells were washed 
with PBS for three times, followed by the incubation with NPSC/siRNA in Opti-MEM. 
The confocal dish was then placed in the live cell imaging chamber with 5% CO2 and at 
37 °C on the confocal microscope. A series of images were taken at 1 min. intervals, and 
the cells were imaged for 25 min. in total. 
Nystatin treatment inhibited siRNA delivery: HeLa cells or deGFP-expressing 
HEK293 were pre-treated with nystatin at a concentration of 100 μg/mL for 1 h at 37 °C, 
followed by an incubation of 40 nM NPSC/siRNA complex. For the cellular uptake 
mechanism study, HeLa cells were incubated with NPSC/Cy3-siRNA (40 nM of Cy3-
siRNA) and FITC-Dextran (0.5 mg/mL) for 2 h, the cells were then washed with PBS 
and imaged under a Zeiss LSM 710 confocal microscope. To study the effect of nystatin 
treatment on gene silencing efficiency, deGFP-expressing HEK293 cells were incubated 
with NPSC/siRNA in the presence of nystatin for 4 h and cultured with fresh medium for 
additional 48 h before CSLM imaging studies and flow cytometry analysis. 
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NPSC/siRNA delivery silenced deGFP expression: Stable deGFP-expressing 
HEK293 cells (1 × 105 cells/well) were seeded in a 24-well plate for 24 h prior to 
delivery, and the cells were washed with PBS for three times before siRNA delivery. At 
the day of transfection, various si_deGFP or scrambled siRNA formulations were added 
to cells and incubated for 4 h in Opti-MEM, followed by an additional 48 h incubation 
with fresh culture medium. The cells were harvested and resuspended in PBS for flow 
cytometry analysis on FACS LSR II (BD Biosciences). Cells suspensions were analyzed 
under the same parameter setting, and at least 10000 events were analyzed for each 
sample. For CLSM imaging of deGFP knockdown, deGFP-expressing HEK293 cells (3.0 
× 105 cells) were seeded in a 35 mm glass bottom culture dish (MatTek, MA) a day 
before experiment. After overnight incubation, the cells were incubated with Opti-MEM 
containing NPSC/si_deGFP with 60 nM siRNA at 37 °C for 4 h, followed by additional 
48 h incubation. The cells were washed with PBS for three times and imaged under a 
Zeiss LSM 710 confocal microscope. 
Cytotoxicity of NPSC/siRNA complex: deGFP-expressing HEK293 cells (1 × 
105 cells/well) were seeded in a 24-well plate 24 h prior to the experiment. At the day of 
experiment, cells were washed by cold PBS and treated with varied concentration of 
NPSC and scramble siRNA complexes (prepared in a similar procedure to that of 
NPSC/si_deGFP complex) for 4 h, followed by an incubation of additional 48 h with 
fresh culture medium. For the comparison of commercial transfection reagent, 
Lipofectamine 2000 and same amount of siRNA was mixed according to manufactures’ 
instruction and dosed to HeLa cells. The cell viability was measured using AlamarBlue 
assay (Invitrogen, CA). 
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NPSC/siPLK1 delivery: MDA-MB-231 cells (2.5 × 104 cells/well) were cultured 
in a 48-well plate for 24 h prior to the experiment. At the day of transfection, 
NPSC/siPLK1 complexes (prepared as mentioned above for si_deGFP complex) were 
diluted by Opti-MEM and incubated with the cells for 4 h, followed by an incubation of 
additional 48 h with fresh culture medium. For negative controls, siPLK1 was replaced 
with scrambled siRNA and exposed to cells at the same concentration. The cell viability 
was measured using AlamarBlue assay according to manufacturer’s instruction. 
Detection of PLK1 expression in siPLK1 transfected cells: MDA-MB-231 
cells (2 × 105) were seeded in 6-well tissue culture plates and incubated at 37 °C in 5% 
CO2 for 24 h until 80% confluence. Various siRNA formulations were added to cells as 
we described in the manuscript. For western blot analysis, the transfected cells were first 
washed once with cold PBS, and then resuspended in 150 μL freshly prepared cell lysis 
buffer (containing 50 mM Tris buffer, pH = 8, 150 mM NaCl, 1% Triton X-100, 10% 
glycerol, 1.5 mM MgCl2, 1mM EGTA) supplemented with protease inhibitor cocktail. 
The lysates were then clarified by centrifugation for 20 min. at 4 °C. The protein 
concentration was determined using BCA Protein Assay Kit (Pierce, IL). Total cell lysate 
protein (33 μg) was separated on 4-12% Bis-Tris PAGE gel and then transferred (at 300 
mA for 45 min) to a PVDF membrane. After blocking the blot with 5% non-fat milk in 
phosphate buffered saline with Tween-20 (PBST, pH 7.2) for 1 h, the membrane was 
incubated with monoclonal antibodies against PLK1 (1:500) in 2% non-fat milk PBST 
solution for 24 h. After incubation in 2% non-fat milk in PBST with goat anti-mouse 
IgG-HRP antibody (1:10 000) for 30 min, bands were visualized using the ECL system 
on a Syngene G-Box (Cambridge, UK). 
 89 
4.5. References
 
1. Whitehead, K. A.; Langer, R.; Anderson, D. G. Nat. Rev. Drug Discov. 2009, 8, 129-
138. 
 
2. Fire, A.; Xu, S.; Montgomery, M.; Kostas, S.; Driver, S.; Mello, C. C. Nature 1998, 
391, 806-811.  
 
3. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Nature 
2001, 411, 494-498. 
 
4. a) Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. Nat. 
Rev. Cancer 2011, 11, 59-67. b) Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, 
D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Nature 2010, 464, 1067-
1070. 
 
5. Pei, Y.; Tuschl, T. Nat. Methods 2006, 3, 670-676. 
 
6. Schroeder, A.; Levins, C. G.; Cortez, C.; Langer, R.; Anderson, D. G. J. Intern. Med. 
2010, 267, 9-21. 
 
7. a) Oh, Y. K.; Park, T. G. Adv. Drug Deliver. Rev. 2009, 61, 850-862. b) Alabi, C. A.; 
Love, K. T.; Sahay, G.; Yin, H.; Luly, K. M.; Langer, R.; Anderson, D. G. Proc. Natl. 
Acad. Sci. U. S. A. 2013, 110, 12881-12886. c) Petros, R. A.; MeSimone, J. D. Nat. Rev. 
Drug Discov. 2010, 9, 615-627. 
 
8 . a) Gary, D. J.; Puri, N.; Won, Y. Y. J. Control. Release 2007, 121, 64-73. b) 
Grandinetti, G.; Reineke, T. M. Mol. Pharm. 2012, 9, 2256-2267. 
 
9. Semple, S. C.; Akinc, J.; Chen, A.; Sandhu, A. P.; Mui, B. L.; Cho, C. K. Sah, D. W.; 
Stebbing, D.; Crosley, E. J.; Yaworski, E.; Hafez, I. M.; Dorkin, J. R.; Qin, J.; Lam, K.; 
Rajeev, K. G.; Wong, K. F.; Jeffs, L. B.; Nechev, L.; Eisenhardt, M. L.; Jayaraman, M.; 
Kazem, M.; Maier, M. A.; Srinivasulu, M.; Weinstein, M. J.; Chen, Q.; Alvarez, R.; 
Barros, S. A.; De, S.; Klimuk, S. K.; Borland, T.; Kosovrasti, V.; Cantley, W. L.; Tam, Y. 
K.; Manoharan, M.; Ciufolini, M. A.; Tracy, M. A.; de Fougerolles, A.; MacLachlan,  I.; 
Cullis,  P. R.; Madden, T. D.; Hope, M. J. Nat.  Biotechnol. 2010, 28, 172-176.  
10. a) Kim, S. T.; Chompoosor, A. Yeh, Y. C.; Agasti, S. S.; Solfiell, D. J.; Rotello, V. 
M. Small 2012, 8, 3253-3256. b) Zheng, D.; Giljohann, D. A.; Chen, D. L.; Massich, M. 
D.; Wang, X. Q.; Iordanov, H.; Mirkin, C. A.; Paller, A. S. Proc. Natl. Acad. Sci. U. S. A. 
2012, 109, 11975-11980. 
 
 
 
 
 
 90 
 
11 . a) Sahay, G.; Querbes, W.; Alabi, C.; Eltoukhy, A.; Sarkar, S.; Zurenko, C.; 
Karagiannis, E.; Love, K.; Chen, D.; Zoncu, R.; Buganim, Y.; Schroeder, A.; Langer, R.; 
Anderson, D. G. Nat. Biotechnol. 2013, 7, 653-658. b) Hong, B. J.; Chipre, A. J.; 
Nguyen, S. T. J. Am. Chem. Soc. 2013, 135, 17655-17658. 
 
12. a) Kurreck, J. Angew. Chem. Int. Ed. 2009, 48, 1378-1398. b) Duan, S. Y.; Yuan, W. 
E.; Wu, F.; Jin, T. Angew. Chem. Int. Ed. 2012, 51, 7938-7941. 
 
13. Kwon, Y. J. Acc. Chem. Res. 2012, 45, 1077-1088. 
 
14. a) Sonawane, N. D.; Szoka, F. C.; Verkman, A. S. J. Biol. Chem. 2003, 278, 44826-
44831. b) Yezhelyev, M. V.; Qi, L.; O'Regan, R. M.; Nie, S.; Gao, X. J. Am. Chem. Soc. 
2008, 130, 9006-9012. c) Ding, Y.; Jiang, Z. W.; Saha, K.; Kim, C. S.; Kim, S. T.; 
Landis, R. F.; Rotello, V. M. Mol. Ther. 2014, 22, 1075-1083. 
 
15. Lv, H.; Zhang, S.; Wang, B.; Cui, S. J. Yan, J. Control. Release 2006, 114, 100-109. 
 
16. a) Vasir, J. K.; Labhasetwar, V. Adv Drug Deliv Rev. 2007, 59, 718-28. b) Lee, S. H.; 
Choi, S. H.; Kim, S. H.; Park, T. G. J. Control Release 2008, 125, 25-32. c) Sahay, G.; 
Querbes, W.; Alabi, C.; Eltoukhy, A.; Sarkar, S.; Zurenko, C.; Karagiannis, E.; Love, K.; 
Chen, D.; Zoncu, R.; Buganim, Y.; Schroeder, A.; Langer, R.; Anderson, D. G. Nature 
Biotech. 2013, 31, 653-658. d) El-Sayed, A.; Futaki, S.; Harashima, H. AAPS. J. 2009, 
11, 13-22. 
 
17. Yang, X. C.; Samanta, B.; Agasti, S. S.; Jeong, Y.; Zhu Z. J.;, Rana, S.; Miranda, O. 
R.; Rotello, V. M. Angew. Chem. Int. Ed. 2011, 50, 477-481. 
 
18. Tang, R.; Kim, C. S.; Solfiell, D. J.; Rana, S.; Mout, R.; Velázquez-Delgado, E. M.; 
Chompoosor, A.; Jeong, Y.; Yan, B.; Zhu, Z.-J.; Kim, C.; Hardy, A.; Rotello, V. M. ACS 
Nano 2013, 7, 6667-6673. 
 
19. a) Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Barik, S. Nat. Med. 2004, 11, 50-55. b) 
Han, L.; Zhao, J.; Zhang, X.; Cao, W.; Hu, X.; Zou, G.; Duan, X.; Liang, X. J. ACS Nano 
2012, 6, 7340-7351. 
 
20. a) Shah, B.; Yin, P. T.; Ghoshal, S.; Lee, K. B. Angew. Chem. Int. Ed. 2013, 52, 
6190-6195. b) Lu, H.; Wang, D.; Kazane, S.; Javahishvili, T.; Tian, F.; Song, F.; Sellers, 
A.; Barnett, B.; Schultz, P. G. J. Am. Chem. Soc. 2013, 135, 13885-13891. 
 
21. Zhang, Z. H.; Cao, W. G.; Jin, H. L.; Lovell, J. F.; Yang, M.; Ding, L. L.; Chen, J.; 
Corbin, I.; Luo, Q. M.; Zheng, G. Angew. Chem. Int. Ed. 2009, 48, 9171-9175. 
 
 
 
 
 91 
 
22. a) Yang, M.; Jin, H. L.; Chen, J.; Ding, L. L.; Ng, K. K.; Lin, Q. Y.; Lovell, J. F.; 
Zhang, Z. H.; Zhang, G. Small 2011, 7, 568-573. b) Lin, Q. Y.; Chen, J.; Ng, K. K.; Cao, 
W. G.; Zhang, Z. H.; Zheng, G. Pharm. Res. 2014, 31, 1438-1449. c) Partlow, K. C.; 
Lanza, G. M.; Wickline, S. A. Biomaterials 2008, 29, 3367-3375. 
 
23. Lu, J. J.; Langer, R.; Chen. J. Mol. Pharm. 2009, 6, 763-771. 
 
24. Love, K. T.; Mahon, K. P.; Leyins, C. G.; Whitehead, K. A.; Querbes, W.; Dorkin, J. 
R.; Qin, J.; Cantley, W.; Qin, L. L.; Racie, T.; Frank-Kamenetsky, M.; Yip, K. N.; 
Alyarez, R.; Sah, D. W. Y.; Fougerolles, A.; Fitzgerald, K.; Koteliansky, V.; Akinc, A.; 
Langer, R.; Anderson, D. G. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1864-1869. 
 
25. a) Martens, S.; McMahon, H. T. Nat. Rev. Mol. Cell. Biol. 2008, 9, 543-556. b) 
Grafmüller, A.; Shillcock, J.; Lipowsky, R. Phys. Rev. Lett. 2007, 98, 218101-218104. c) 
Roy, S. M.;  Sarkar, M. J. Lipids. 2011, 2011, 528784. 
 
26. Sun, Y.; Tien, P. Crit. Rev. Microbiol. 2013, 39, 166-179. 
 
27. Krebs, M. D.; Jeon, O.; Alsberg, E. J. Am. Chem. Soc. 2009, 131, 9204- 9206. 
 
28. a) Degenhardt, Y.; Lampkin, T.; Strebhardt, K.; Ullrich, A. Nat. Rev. Cancer 2006, 6, 
321-330. b) McNamara, J. O.; Andrechek, E. R.; Wang, Y.; Viles, K. D.; Rempel, R. E.; 
Gilboa, E.; Sullenger, B. A.; Giangrande, P. H. Nat. Biotechnol. 2006, 24, 1005-1015. 
 
29. Yao, Y. D.; Sun, T. M.; Huang, S. Y.; Dou, S.; Lin, L.; Chen, J. N.; Ruan, J. B.; Mao, 
C. Q.; Yu, F. Y.; Z, M. S.; Zang, J. Y.; Liu, Q.; Su, F. X.; Zhang, P.; Lieberman, J.; 
Wang, J.; Song, E. W. Sci. Transl. Med. 2012, 4, 130ra48. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
CHAPTER 5 
SIMULTANEOUS CYTOSOLIC DELIVERY OF A CHEMOTHERAPEUTIC 
AND SIRNA FOR ENHANCED BREAST CANCER THERAPY  
 
5.1. Introduction 
Breast cancer is the most common type of cancer affecting women worldwide; 
approximately 1 in 8 women will develop invasive breast cancer at some point during 
their lifetime.1 Traditional therapies for breast cancer include chemo- and radio-therapies, 
treatments that often lose effectiveness over time and have substantial off-target effects. 
There has been a significant drive in research to discover innovative methods for treating 
breast cancer in safer, more robust and successful ways. 
Over the past decade there has been considerable effort to capitalize on the 
potential of small interfering RNA (siRNA) to act as an anti-cancer therapy.2, 3, 4 siRNA 
can be introduced into cells to induce the endogenous RNA interference (RNAi) 
mechanism, by which the mRNA of specific proteins are degraded, resulting in 
corresponding knockdown. 5  By introducing siRNA targeted to the messenger RNA 
(mRNA) of proteins that promote cancer survival and expansion, the progression of 
cancer may be inhibited or even reversed outright.6 Due to the high specificity and low 
toxicity of siRNA, there have been numerous investigations toward its use as an 
alternative to traditional cancer treatments. 7, 8, 9, 10 Because siRNA is both large and 
strongly negatively charged, a delivery platform is required to introduce exogenous 
siRNA into cells for induced RNAi.11  Many different vehicles have been synthesized for 
this purpose; however, the majority of these rely on endocytosis to enter cells, and 
therefore require an endosomal escape strategy for siRNA to reach the cytoplasm, where 
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RNAi occurs.2, 3 ,4 Without endosomal escape, the siRNA will remain trapped, decreasing 
agent efficacy. There are several different strategies that have been developed for release, 
including the proton sponge effect, endosome pore formation, and photo-activated 
endosome disruption.12 While these methods differ in their specific mechanisms, they 
typically involve rupture of the endosomal membrane caused by a chemical or physical 
force. However, the escape efficiency of the delivered cargo is often poor, resulting in an 
inevitable decrease in potency for vehicles relying on endocytosis. Additionally, 
strategies for endosomal escape often show undesirable, non-specific cellular toxicity.  
In order to solve problems associated with existing delivery vehicles, our group 
developed the nanoparticle stabilized capsule (NPSC).13 The NPSCs consist of a linoleic 
acid oil core coated in arginine functionalized gold nanoparticles (Arg-AuNP) 
electrostatically associated with negatively charged molecules such as siRNA (Scheme 
5.1). Instead of relying on endocytosis to enter cells, NPSCs use an entirely different 
mechanism, circumventing endosomal entrapment. Previous work has demonstrated that 
cargo delivered by NPSCs enters the cytosol directly, allowing for effective delivery of 
the encapsulated payload.13 Evidence suggests that the linoleic acid oil core of the NPSC 
causes the vehicle to utilize a cholesterol dependent “membrane fusion” mechanism: the 
oil core fuses with the lipid portion of the cell membrane upon contact, resulting in direct 
entry of associated cargoes into the cytosol of treated cells.13 By entering the cells via this 
alternative mechanism, NPSCs avoid decreased potency and the need to employ a means 
for endosomal escape, giving them enhanced promise as efficient, non-toxic co-delivery 
vehicles. 
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Scheme 5.1. Schematic presentation of NPSC-mediated co-delivery of both siSurv and 
tamoxifen for enhanced cancer therapy. 
 
In order to increase the therapeutic efficacy of siRNA, therapies have been 
designed that combine the targeted knockdown capabilities of siRNA with the more 
broadly cytotoxic power of small molecule drugs to create '1-2 punch' therapies.2 A 
variety of platforms have been developed for the simultaneous delivery of siRNA and 
drugs, including polymers,14  liposomes,15  and mesoporous silica nanoparticles.16  In 
general, these nanoparticles encapsulate siRNA via electrostatic interactions, with 
anticancer drugs loaded by either non-covalent encapsulation or covalent conjugation.17 
These co-delivery strategies have resulted in improved cancer therapies by countering 
biological compensation and by accessing multiple context-specific targets. 
While co-delivery vehicles have shown promise, they face not only all of the 
challenges that are encountered in individual siRNA or small-molecule drug delivery, but 
also unique issues. 18 , 19, 20, 21, 22, 23  The syntheses of vehicles that can tolerate both 
aqueous and hydrophobic cargoes can be cumbersome and unwieldy.22 Furthermore, 
endocytosis remains the primary method of uptake for these vehicles, which results in 
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endosomal entrapment of both cargoes, reducing the total concentration of successfully 
delivered therapeutic.24 Hydrophobic small molecule drugs pose an additional 
challenge since they are not compatible with the aqueous environment of the body, and 
exhibit unique pharmacokinetic and pharmacodynamic features.22 Because of their 
hydrophobicity, these molecules have retention and excretion characteristics that are 
significantly different from those of aqueous molecules. This also presents an issue for 
co-delivery as vehicle modifications meeting the requirements for hydrophobic drug 
incorporation may alter the release profile.22 Because of these challenges, there has been 
little effort towards developing potentially powerful drugs that do not have favorable 
solubility profiles; this trend can be reversed by developing effective delivery vehicles for 
hydrophobic drugs.25 
We have previously reported the use of nanoparticle-stabilized capsules for 
independent deliveries of proteins, siRNA, and drugs.13, 26, 27 The outer positively charged 
shell of the “nanocapsule” structure allows interaction with negatively charged molecules 
such as siRNA and certain proteins, while the inner oil core facilitates encapsulation of 
hydrophobic chemotherapeutics. Here, we combine their capacities to associate with 
siRNA electrostatically and solubilize hydrophobic drugs in the oil layer to generate the 
first NPSC dual-delivery agents.  By co-loading NPSCs concomitantly with siRNA and 
anti-cancer drugs, we not only reduced the number of doses required to treat the cells 
with multiple therapeutics, but also anticipate that the dual-loaded entities will have a 
greater anti-cancer therapeutic effect than individual treatments alone.  
The therapeutic combination chosen for NPSC co-delivery is survivin-targeted 
siRNA (siSurv) and tamoxifen. One of the core elements of this strategy is delivery of 
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siRNA targeted to the cancer-related protein survivin. Survivin is an inhibitor of 
apoptosis protein (IAP) that is over-expressed in nearly every type of cancer.19 The 
delivery of siSurv decreases survivin expression, thus preventing the caspase-inhibiting 
action of the functional survivin protein, enabling apoptosis. 28 Tamoxifen (TM) is a 
highly hydrophobic cytostatic and cytotoxic chemotherapeutic used clinically for the 
treatment of estrogen receptor positive breast cancers.20, 29  It has been shown that cancer 
cells that only receive a single treatment of tamoxifen alone can either evade apoptosis by 
over-expressing survivin, while those that are treated with siSurv alone do not have 
sufficient impetus to undergo apoptosis following survivin knockdown.30 For this reason, 
we concomitantly deliver the two via NPSCs to yield increased breast cancer cell death 
by both halting growth of cancer cells, thereby driving them towards apoptosis, and 
removing their ability to avoid it, in a single treatment.  
In this study, we demonstrate that NPSCs are highly effective in the simultaneous 
delivery of anti-Survivin siRNA and tamoxifen to MCF7 human breast cancer cells. We 
confirm NPSC-mediated delivery of both to the cytoplasm, and ensure decreased survivin 
mRNA levels following treatment with siSurv. To demonstrate the enhanced anti-cancer 
efficiency of the dual-loaded siRNA, we used cell viability assays and apoptotic staining. 
As a result, we find that not only does NPSC encapsulation increase the effectiveness of 
tamoxifen treatment, but that the siRNA/drug combination is more effective in inducing 
cancer cell death than individual treatments alone. These results illustrate that the NPSC 
vehicle holds promise as an effective treatment vector for cancer by facilitating the 
effective co-delivery of various therapeutics. 
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5.2. Results and Discussion 
Prior to co-delivery experiments, NPSCs were fabricated and characterized. 
NPSCs were prepared as described previously.13, 26, 27 In order to determine the quality of 
the NPSCs synthesized, TEM images and DLS measurements were obtained to determine 
the relative size and morphology of the fabricated capsules (Figure 5.1). These 
measurements demonstrated a consistent spherical morphology and a stable size of 
approximately 150 nm in diameter. 
 
Figure 5.1. a) Dynamic light scattering (DLS) measurements of size (number average) of 
NPSC/drug (red line), NPSC/siRNA (blue line), and NPSC/siRNA/drug complexes 
(black line). b) TEM images of NPSC/siRNA/drug complexes.  
 
Having confirmed the successful fabrication of NPSCs, we determined whether 
NPSCs could deliver siRNA and a hydrophobic small molecule simultaneously into the 
cytosol. We have previously reported that the NPSCs can efficiently deliver drugs or 
siRNA individually into the cytosol of treated cells.13, 26, 27 To confirm co-delivery, FAM-
labeled scramble sequence siRNA (FAM-siRNA) was incorporated onto the surface of 
NPSCs that had Nile Red dissolved in the interior oil core. Using confocal laser scanning 
microscopy (CLSM) to monitor uptake, we observed significant and diffuse green and 
red fluorescence throughout the cytosol following treatment (Figure 5.2). This pattern 
suggests that the fluorophore has free access to the entire cytosol since an endocytotic 
route would lead to endosomal entrapment, which should be apparent via “punctuate” 
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fluorescence signal and is not observed. Additionally, there is significant overlap of the 
red and green fluorescence signals, providing evidence for co-localization of both cargoes.  
 
Figure 5.2. Confocal microscopy images of MCF-7 cells following 2 hour treatment with 
NPSC/FAM-siRNA/Nile red complex.  Scale bar: 20 μm. 
 
To confirm the ability of NPSCs to effectively deliver siRNA for knock down of 
survivin, Real Time-Polymerase Chain Reaction (RT-PCR) was used to determine the 
change in mRNA expression following treatment (Figure 5.3). Both the NPSCs loaded 
with siSurv alone and NPSCs loaded with tamoxifen and siSurv resulted in an 
approximately 70% decrease in survivin mRNA levels. Concurrently, the control groups 
that did not receive siSurv treatment showed minimal survivin mRNA change compared 
to untreated control. This data is evidence of the ability of NPSCs to efficiently deliver 
siRNA into the cytosol to elicit specific RNAi to occur. 
We next investigated the therapeutic potential of siRNA and tamoxifen co-
delivery using NPSCs. To evaluate the efficacy of this combination, an Alamar Blue cell 
viability assay was performed (Figure 5.4). As shown in Figure 5.4, the NPSCs with both 
siSurv and tamoxifen reduce cell viability more than either of the individual treatments at 
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any concentration level. With 40 nM siRNA and 2.6 μM tamoxifen, the combination 
outperforms either individual treatment by a minimum of 30% more decrease in cell 
viability, resulting in 80% decrease overall. Loading either siSurv or tamoxifen 
individually into the NPSCs shows dose-dependent decrease in cell viability. 40 nM 
siSurv/NPSC treatment resulted in a 50% decrease in cell viability, while 2.6 μm 
tamoxifen/NPSC treatment caused a 27% decrease in cell viability. This result suggests 
that not only is the combination of tamoxifen and siSurv efficient at killing breast cancer 
cells, but that NPSCs are an effective platform for co-delivery. Interestingly, NPSC 
delivery of tamoxifen results in a greater decrease in cell viability than free tamoxifen 
even at much higher doses.  
 
Figure 5.3. RT-PCR of normalized survivin mRNA levels in MCF-7 cells 48 hours after 
treatment. Cell control (non-treated), NPSC/Scr (Scr: 40 nM), NPSC/Scr/TM (Scr: 40 nM, 
and TM: 2.6 μM), NPSC/Surv (Surv: 40 nM), NPSC/Surv/TM (Surv: 40 nM, and TM: 
2.6 μM), and free TM (10 μM).   
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Figure 5.4. Alamar blue evaluation of MCF-7 cell viability. Cells were treated with 
NPSC/Scr, NPSC/Scr/TM, NPSC/Surv, NPSCs/Surv/TM complexes, and free TM at 
indicated siRNA and drug concentrations. The error bars represent the standard 
deviations of three parallel measurements. 
 
 
Figure 5.5. Viability of MCF-7 cells treated with NPSC/siRNA (red square) complexes 
at indicated siRNA concentrations as measured using an Alamar blue assay. Scrambled 
siRNA was used to complex with NPSC. The error bars represent the standard deviations 
of three parallel measurements. 
 
Because NPSCs show nearly undetectable toxicity at high doses (Figure 5.5), this 
may be the result of active tamoxifen delivery into the cell membrane via the unique 
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membrane fusion entry mechanism of the capsules versus the passive diffusion that 
occurs with free tamoxifen.20 This is another major benefit of the NPSC system as the 
increased potency reduces the required concentration for a therapeutic effect, decreasing 
the risk of side effects that are common with chemotherapeutics.  
 
Figure 5.6. Confocal microscopy images of MCF-7 cells after 48 hours treatment with 
NPSC/Surv/TM (siSurv: 35 nM, and TM: 2.3 μM), NPSC/Scr (siScr: 35 nM), 
NPSC/Surv (siSurv: 35 nM), and NPSC/TM (TM: 2.3 μM) complex. Apoptotic cells 
were stained with Yopro-1 (green fluorescence). Scale bar: 100 μm. 
 
The apparent increase in cell death following co-delivery was further confirmed 
by staining of apoptotic nuclei with YOPRO-1 (Figure 5.6), where cells treated with 
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NPSCs carrying both chemotherapeutic cargoes displayed a major increase in fluorescent 
nuclei, versus controls. This experiment provides evidence that this treatment strategy 
will have a wide therapeutic window that is beneficial for long term cancer treatments.  
5.3. Conclusions 
We have reported the fabrication and development of a combination siRNA and 
hydrophobic anti-cancer drug delivery platform using NPSCs. NPSCs composed of Arg-
AuNP and linoleic acid provide an ideal combination of chemical functionalities and 
interacting forces to effectively bind and encapsulate anti-survivin siRNA and tamoxifen, 
and are able to deliver them efficiently to the cytosol in a non-endocytotic manner. Not 
only did the co-delivery of both therapeutics result in the increased efficacy of cancer cell 
death, incorporation of tamoxifen in the NPSCs resulted in higher cell death than 
tamoxifen alone, a fact that could be attributed to active delivery of tamoxifen in aqueous 
media by the capsules. NPSC-mediated co-delivery is highly promising in terms of being 
able to maximize the usefulness of different therapies and reduce the probability of 
adverse side effects that are currently common in most cancer therapies.22 We believe 
that the NPSC platform can be extended to a variety of combination therapies involving 
different small molecule drugs and biologics in order to produce advanced cancer 
therapies. Future work will develop the NPSC platform as a therapeutic vehicle further by 
evaluating its in vivo delivery characteristics and utilizing the co-delivery capabilities of 
the vehicle to deliver different cargo combinations develop new therapeutic approaches 
for different disease models.      
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5.4. Experimental Section 
General methods: All standard reagents and chemicals used were purchased 
from Fisher Scientific or Sigma-Aldrich, except where noted. Chloroauric acid used for 
gold nanoparticle synthesis was bought from Strem Chemicals Inc. (Newburyport, MA). 
Validated siSurv was purchased from Sigma-Aldrich. Scrambled siRNA and FAM-
labeled scrambled siRNA were purchased from Invitrogen (Carlsbad, CA). Transmission 
electron microscopy (TEM) was performed on a JEOL-2010 microscope with an 
accelerating voltage of 200 kV. Particle size was measured using a Malvern Zetasizer 
(Nano series, Malvern Instruments Inc, USA) with a He-Ne laser (633 nm) and a 
backscattering angle of 173º. Confocal microscopy images were obtained on an Eclipse 
Ti-E microscope (Nikon, Tokyo, Japan) using a 63X or 10X objective.  
NPSC, drug and siRNA complexation: The arginine-functionalized AuNP 
(Arg-AuNP) and NPSC were synthesized according to our previous report.26, 27 Briefly, 
tamoxifen was dissolved into linoleic acid at 120 mg/mL. Then, 1 μL of linoleic acid was 
mixed with 500 μL of phosphate buffer (5 mM, pH = 7.4) containing 1 μM Arg-AuNP 
and agitated by an amalgamator at 5000 rpm for 100 s to form emulsions. Then, 10 μL of 
the emulsion was added into 90 μL of 5 mM phosphate buffer containing 2.5 μM Arg-
AuNP and incubated for 10 min. at room temperature to afford NPSC/drug/siRNA 
complex.  
Cell culture: MCF7 cells were purchased from American Type Culture 
Collection (ATCC, Manassas, VA). Cells were cultured at 37 °C under humidified 
atmosphere with 5% CO2. High-glucose DMEM (4.5 g/L) with 10% fetal bovine serum 
(FBS), 1% antibiotic (100 U/mL penicillin and 100 μg/mL streptomycin) was used for 
culturing cells.  
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Fluorescently labeled siRNA and oil delivery: For confocal laser scanning 
microscopy (CLSM) imaging of cellular uptake of the NPSC/siRNA complex, MCF7 
cells (8.0×104 cells) were seeded in each well of a 4 chamber Lab-Tek II chambered 
coverglass system (Nunc, NY) one day prior to the experiment. On the day of delivery, 
the culture medium was replaced with Opti-MEM containing 40 nM NPSC/FAM-
siRNA/Nile Red; the cells were subsequently incubated for 2 h at 37 °C. After 2 h, the 
media was removed, and the cells were washed once with cold phosphate buffer saline 
(PBS); fluorescence imaging was performed in PBS using an Eclipse Ti-E microscope.  
NPSC/siSurv delivery for evaluation of survivin expression: MCF7 cells (2 × 
104 cells/well) were seeded in a 24-well plate for 24 h prior to delivery. On the day of 
transfection, the cells were washed with PBS three times, followed by the addition of 
various siSurv or scrambled siRNA formulations in Opti-MEM, which were incubated 
with the cells for 3 h. The Opti-MEM was replaced with fresh culture media, and the cells 
were incubated for an additional 48 h prior to further analysis.  
RNA extraction: Approximately 1.5 μg of RNA was harvested using the Pure 
Link RNA Mini kit (Ambion) following the manufacturer’s instructions. Superscript IV 
reverse transcriptase was used for conversion of approximately 150 ng of RNA to cDNA, 
along with RNaseOut, 10 mM dNTPs, and 50 μm random hexamers (Thermo Fisher 
Scientific), also following manufacturer’s instructions.  
Real Time Polymerase Chain Reaction (RT-PCR): RT-PCR was performed on 
cDNA as prepared above using a CFX Connect Real Time System with iTaq Universal 
SYBR Green Supermix (Biorad). All DNA primers were purchased from Integrated DNA 
Technologies (Caralville, Iowa). The following sequences were used: GAPDH Forward 
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(5’- CTT CTT TTG CGT CGC CAG CC-3’), Reverse (5’-ATT CCG TTG ACT CCG 
ACC TTC-3’); Survivin Forward (5’- GAC GAC CCC ATA GAG GAA CA- 3’), 
Reverse (5’-CTT GAC AGA AAG GAA AGC GCA-3’). The samples were incubated as 
follows: the samples were first activated at 50 ⁰C for 2 min then 95 ⁰C for 2 min. Then 
denaturing occurred at 95 ⁰C for 5 min followed by annealing at 60 ⁰C. The 
denature/anneal process was repeated over 40 cycles. At the conclusion a melting 
analysis was performed  holding at 95 ⁰C for 10 min, then 60 ⁰C for 5 min and then back 
to 95 ⁰C for 5 min. Relative survivin expression was determined by comparing the Ct 
value of survivin to that of GAPDH, used as a housekeeping gene, by the 2^ΔΔCt method.  
Three biological replicates were performed for each control group and three technical 
replicates were used for each biological replicate.  
 Cytotoxicity of NPSC/siRNA complex: MCF7 cells (2 × 104 cells/well) were 
seeded in a 24-well plate 24 h prior to the experiment. On the day of experiment, cells 
were washed with PBS and treated with varied concentrations of NPSC and 
siRNA/tamoxifen complexes in OptiMem (prepared similarly to NPSC/siSurv complex 
solution described above) for 3 h. The treatment media was replaced with fresh culture 
media, and cells were incubated for an additional 48 h. For cells treated with free 
tamoxifen, tamoxifen was dissolved in DMSO and added directly to cell solutions. The 
cell viability was determined using Alamar Blue assay reagent (Invitrogen, CA) using a 
SpectraMax M2 plate reader exciting at 560 nm and detecting emission at 590 nm. Three 
biological replicates were performed for viability determination. 
Apoptosis Assay: MCF7 cells (2.0 × 104 cells) were seeded in each well of a 4 
chamber Lab-Tek II chambered coverglass system (Nunc, NY) a day before the 
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experiment. On the day of, cells were washed with cold PBS and treated with various 
concentrations of NPSC and siRNA/tamoxifen complexes in OptiMEM for 3 h, followed 
by replacement of media. For cells treated with free tamoxifen, tamoxifen was dissolved 
in DMSO and added directly to cell solutions. The cells were incubated for an additional 
48 h, after which the media was replaced with fresh growth media containing 1 mM YO-
PRO-1 (ThermoFisher Scientific) apoptotic staining reagent, and incubated for 30 min at 
37 °C. After removing medium, the cells were washed and replaced with cold phosphate 
buffer saline (PBS) for fluorescence imaging under an Eclipse Ti-E microscope. 
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CHAPTER 6 
NANOCAPSULE-MEDIATED CYTOSOLIC SIRNA DELIVERY FOR ANTI-
INFLAMMATORY TREATMENT   
 
6.1. Introduction 
Inflammation is a complex biological reaction of the immune system in response 
to microbial, autoimmune, metabolic or physical insults.1, 2, 3, 4 Normally, the forces of 
inflammation are held in a delicate balance to protect the body by removing harmful 
stimuli, initiating the healing process, and cleaning up debris. Uncontrolled inflammation, 
however, ignites various autoimmune disorders, including inflammatory bowel disease, 
multiple sclerosis, and rheumatoid arthritis.5, 6, 7  
Macrophages play a critical role in the initiation and maintenance of inflammation 
by secreting proinflammatory cytokines. 8 , 9  Suppressing cytokine expression by 
macrophages has been proved to be a beneficial approach for the treatment of 
inflammatory diseases.10, 11 For example, up-regulation of tumor necrosis factor-α (TNF-
α) is observed in a large number of autoimmune disorders. To combat this, TNF-α 
monoclonal antibodies or recombinant TNF-α receptors have been used to interfere with 
the inflammation cascade.12, 13 Despite the effectiveness of these therapeutics to regulate 
proinflammatory cytokines, they are often associated with high costs, generation of 
autoimmune response to antibodies, and potential toxic side effects following chronic 
antibody treatment. New therapeutics that enables highly efficient immunomodulation 
with low autoimmune response are desired for immune therapy. 
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Scheme 6.1. Schematic outline of nanoparticle stabilized nanocapsule/siRNA-mediated 
in vivo TNF-α silencing in lipopolysaccharide-induced mouse inflammation. The anti-
inflammatory nanocapsule was prepared by assembling siRNA targeting TNF-α with 
cationic arginine functionalized gold nanoparticles, with the resulting ensemble self-
assembled onto the surface of fatty acid nanodroplets to form a NPSC/siRNA 
nanocomplex. 
 
RNA interference (RNAi) offers an alternative approach to precisely manipulate 
the immune system at a molecular and cellular level; there are potential applications for 
the treatment of immune disorders by knocking down proinflammatory cytokine (e.g., 
TNF-α) expression using small interfering RNA (siRNA).14, 15, 16, 17, 18, 19, 20 The efficient 
delivery of siRNA to the cytosol of desired cells, however, remains a challenge to 
realizing the promise of RNAi for immune therapy. 21 , 22, 23, 24  A large number of 
nanocarriers have been developed for siRNA delivery, mainly relying on endocytic 
pathways to enter cells.25, 26, 27 Despite the success and effectiveness of these methods for 
RNAi, the endocytosed siRNA usually has difficulty escaping from the endosomes and 
reaching the cytosol, which subsequently decrease the RNAi efficiency. We recently 
have developed nanoparticle-stabilized nanocapsules (NPSCs) for direct cytosolic siRNA 
delivery, which avoid the endosomal entrapment of siRNA. 28  The NPSC/siRNA 
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assembly relies on stabilization through supramolecular interactions between the cationic 
nanoparticle shell and complementary hydrophobic/anionic “oil” component. These 
capsules are further stabilized through lateral electrostatic interactions at the NPSC 
surface between nanoparticles and anionic siRNA. Using this method, we have been able 
to assemble siRNA-loaded nanocapsules as small as 150 nm, capable of preventing 
siRNA from RNase and serum degradation, and delivering siRNA directly to the cytosol 
by bypassing endocytic pathways.  
Here, we report the use of NPSCs for efficient delivery of siRNA to macrophages, 
and modulation of cellular immune response in vitro and in vivo (Scheme 6.1). We 
initially studied the cytosolic delivery of siRNA to regulate TNF-α gene of murine 
macrophage RAW 264.7 cells stimulated with lipopolysaccharide (LPS). In vivo 
biodistribution studies have shown that more than 80% of systematically administrated 
NPSC/siRNA is accumulated in mouse spleen with concomitant gene knockdown. 
Moreover, injection of NPSC/siRNA targeting TNF-α into a LPS-challenged mouse leads 
to a significant and systemic TNF-α depletion and immunomodulation. The potent in vivo 
siRNA delivery and effective gene regulation using NPSCs/siRNA formulation provides 
an exciting approach for the treatment of inflammatory diseases.  
6.2. Results and Discussion 
NPSCs were fabricated according to our previous report.28 NPSC/siRNA 
displayed an average size of 180 ± 10 nm in diameter, as measured by dynamic light 
scattering (DLS) analysis. We first explored the direct cytosolic delivery of siRNA to 
murine macrophage RAW 264.7 cells, and subsequently studied gene knockdown 
efficiency with macrophages following the delivery of siRNA targeting TNF-α.  
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Figure 6.1. In vitro delivery of siRNA into RAW 264.7 cells. a) Confocal microscopy 
images of RAW 264.7 cells treated with 40 nM Cy3-labeled siRNA delivered with 
NPSCs. b) Representative flow cytometry plots of Cy3-siRNA positive RAW 264.7 cells. 
RAW 264.7 cells treated with PBS (top), or 40 nM NPSC/Cy3-siRNA (bottom) for 2 
hours were harvested for flow cytometry analysis. c) In vitro delivery of NPSC/si_TNF-α 
effectively decreased TNF-α production from LPS stimulation. RAW 264.7 cells were 
treated with PBS, NPSC/si_TNF-α complexes at indicated si_TNF-α concentration, 
NPSC/si_Scr (50 nM), and free si_TNF-α (50 nM) for 24 hours, followed by 3 hours LPS 
stimulation (1 µg/mL). The supernatant TNF-α was measured by ELISA. The error bars 
represent the standard deviations of three parallel measurements. 
 
To this end, we treated RAW 264.7 cells with siRNA-loaded NPSCs, in which the 
siRNA was fluorescently labeled with Cy3 to track cellular uptake and sub-cellular 
localization.29, 30 Both confocal laser scanning microscopy imaging and flow cytometry 
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analysis confirmed that NPSC/Cy3-siRNA nanoparticle was efficiently internalized by 
RAW 264.7 cells. As shown in Figure 6.1a, significant accumulation and diffusion of 
Cy3 red fluorescence throughout the cytosol was observed for the cells treated with 40 
nM NPSC/Cy3-siRNA, indicating a direct cytosolic siRNA delivery via a non-endocytic 
route associated with NPSC-facilitated siRNA delivery.28 Moreover, the siRNA 
transfection efficiency was as high as 90% in the presence of 40 nM siRNA (Figure 6.1b), 
with dose-dependent siRNA uptake observed (Figure 6.2), suggesting that NPSC-
mediated delivery of siRNA to macrophages can be as efficient as state-of-the-art 
transfection reagents. 
 
Figure 6.2. RAW 264.7 cells were treated with NPSC/Cy3-siRNA containing varied 
concentration of siRNA for 2 h. The error bars represent the standard deviations of three 
parallel measurements. 
 
We next investigated the efficacy of NPSC-facilitated siRNA delivery to knock 
down TNF-α expression. The secretion profile of TNF-α from RAW 264.7 macrophages 
with lipopolysaccharide (1 µg/mL) stimulus was used as the determinant for gene silence 
efficiency. 31 , 32  As shown in Figure 6.1c, the treatment of RAW 264.7 cells with 
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NPSCs/si_TNF-α (50 nM siRNA) for 24 h resulted in 90%  decreased TNF-α secretion 
compared to cells treated with PBS.  
 
Figure 6.3. Viability of RAW 264.7 cells after 24 h incubation of NPSC/si_Scr, and 
another 3 hours of incubation a) without, and b) with LPS (1µg/mL) stimulation. 
Scrambled siRNA was used to complex with NPSC. The error bars represent the standard 
deviations of three parallel measurements. 
 
In addition, the NPSC/si_TNF-α complex suppressed TNF-α expression in a 
siRNA concentration dependent manner. When the concentration of siRNA added to cells 
increased from 10 nM to 50 nM, the TNF-α suppression was increased from 10% to 90% 
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accordingly (Figure 6.1c). Moreover, treating cells with si_TNF-α alone or NPSCs 
containing scramble siRNA had no effect on silencing TNF-α expression. In addition, 
NPSCs are highly biocompatible and safe for the delivery of siRNA to macrophages, 
with no obvious toxicity observed when the concentration of NPSCs/siRNA exposed to 
RAW 264.7 cells increased from 10 to 60 nM (Figure 6.3).  
 
Figure 6.4. In vivo distribution and gene silencing using NPSC/siRNA. a) Biodistribution 
of gold in mouse organs after intravenous injection of NPSC/siRNA. The amount of gold 
was quantitatively analyzed by ICP-MS. b) In vivo delivery of NPSC/si_GAPDH 
effectively decreased splenic GAPDH mRNA levels. BALB/c mice were i.v. injected 
twice with NPSC/siRNA complexes at a siRNA dose of 0.14 mg/kg at a 2 day interval, 
and organs were harvested 3 days after final injection (n = 3). 
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Having confirmed that NPSCs are effective for the delivery of siRNA to RAW 
264.7 cells for targeted gene knockdown, we next investigated the potential for siRNA 
delivery in vivo. To characterize the tissue distribution of NPSC/siRNA, we initially 
chose the ubiquitously highly expressed housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GADPH) as a target. 33, 34 The efficient accumulation of NPSCs and 
subsequent GAPDH gene silencing provide detailed biodistribution information for 
NPSCs. To this end, NPSCs formulated with siRNA targeting GAPDH (si_GADPH) 
were injected intravenously into BALB/c mice twice, with a 2 day interval in between, at 
a dose of 0.14 mg/kg siRNA each. The tissues were harvested 3 days after the second 
injection for further analysis. Two parallel analyses were performed to assess the in vivo 
distribution of NPSC/siRNA nanoparticle, one using inductively coupled plasma mass 
spectrometry (ICP-MS) to determine the gold accumulation in different tissues,35, 36 and 
the other using reverse transcription polymerase chain reaction (RT-PCR) to quantify 
GAPDH mRNA change following the injections of different siRNA formulations.37, 38  
Quantifying the amount of gold in different tissues revealed that 80% and 10% of 
NPSC/siRNA nanoparticle were accumulated in spleen and liver respectively, while less 
than 5% of NPSC/siRNA nanoparticle were accumulated in other tissues, including 
kidney, lung, and heart (Figure 6.4a). The predominant accumulation of NPSC/siRNA in 
the spleen is mostly due to the splenic filtration of nanoparticles, which is frequently 
observed for non-deformable entities that are larger than the width of cell slits (200–250 
nm).39, 40 
Given the targeted delivery of NPSC/siRNA to spleen, and the efficient delivery 
of siRNA to the macrophage cytosol using NPSCs (Figure 6.1), we predicted specific and 
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potent gene silencing in the spleen after a systematic injection of NPSC/si_GADPH. The 
efficacy of NPSC/si_GADPH for in vivo GAPDH silencing in different tissues was 
analyzed by quantifying GAPDH mRNA, with β-actin expression as an internal 
comparison. The systematic injection of NPSC/si_GAPDH nanoparticles into BALB/c 
mice at total siRNA dose of 0.28 mg/kg, resulted in 80% decrease of GAPDH mRNA in 
spleen (Figure 6.4b) compared to mice injected with scramble NPSCs/siRNA. Meanwhile, 
we observed slight, but not significant GAPDH silencing in the liver, with no obvious 
GAPDH silencing in lung, kidney, and heart. Taken together, the ICP-MS study and in 
vivo GAPDH gene silencing highlights the potency of NPSCs for spleen targeted siRNA 
delivery and gene regulation. Importantly, NPSCs are highly biocompatible and safe for 
in vivo siRNA delivery. No significant bodyweight change was noted for mice injected 
with NPSC/siRNA nanoparticle compared to that with PBS injection (Figure 6.5). 
 
Figure 6.5. Average mouse weight changes during the course of treatment with PBS, 
NPSC/si_Scr, and NPSC/si_GAPDH (n = 3, mean ± standard deviation). 
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Figure 6.6. Clinical chemistry parameters. Parameters were evaluated for negative 
control (PBS), NPSC/si_Scr, and NPSC/si_GAPDH injected BALB/c mice. The mice 
were injected twice with NPSC/siRNA complexes at a siRNA dose of 0.14 mg/kg at 2 
day interval. Blood was drawn 3 days post-final injection. There were no statistically 
significant changes in any of the clinical chemistry parameters for any of the treated 
groups compared to controls. Error bars represent standard deviation (n = 3). 
 
Moreover, an assay for clinical chemistry parameters demonstrated that the 
NPSCs have very low liver toxicity and low immune response for in vivo siRNA delivery 
(Figure 6.6). The biomedical markers for liver damage, including alanine transaminase, 
aspartate transaminase, alkaline phosphatase, total bilirubin in serum were measured 3 
days after the last NPSC/si_Scr or NPSC/si_GAPDH injection (total siRNA dose of 0.28 
mg/kg). 41  The results show minimal change compared to that injected with PBS, 
indicating no acute toxicity at this siRNA dose. It was also noted that following the 
administration of NPSC/siRNA, there was no significant change of TNF-α, and IFN-γ 
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levels in serum (Figure 6.7), demonstrating that NPSCs/siRNA did not activate pro-
inflammatory cytokines or induce innate immune responses.  
 
Figure 6.7. No significant change of serum a) TNF-α, and b) IFN-γ level following the 
injection of PBS, NPSC/si_Scr, and NPSC/si_GAPDH to BALB/c mouse. The TNF-α 
and IFN-γ level were measured using the ELISA kits (R&D systems, MN), and 
normalized to the PBS treated group (n = 3, mean ± standard deviation). 
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Figure 6.8. In vivo delivery of NPSC/si_TNF-α effectively decreased serum TNF-α 
production from LPS-induced inflammation. BALB/c mice were i.v. injected twice with 
NPSC/siRNA complexes at a siRNA dose of 0.28 mg/kg in 6 hour intervals, followed by 
LPS administration (10 µg/kg, or 5 mg/mouse, i.p.) 24 hours later. Serum TNF-α was 
measured by ELISA 1.5 hours after administration of LPS (n = 3). 
 
Next, we studied whether the efficient delivery of NPSC/siRNA to the spleen 
could regulate TNF-α secretion and modulate the immune response in a LPS-challenged 
mouse model. 42 , 43, 44, 45, 46  To this end, BALB/c mice were i.v. injected with PBS, 
NPSC/si_TNF-α or NPSC/si_Scr twice at a siRNA dose of 0.28 mg/kg, 24 hours prior to 
LPS administration. Mice were sacrificed 1.5 h post LPS treatment, and the serum was 
collected and processed for a TNF-α assay. As shown in Figure 6.8, NPSC/si_TNF-α 
nanoparticle treated mice displayed 60% reduced serum TNF-α secretion compared to 
PBS and NPSC/si_Scr treated mice (LPS: 5 mg/kg). Importantly, we observed effective 
TNF-α gene knockdown at a 9-fold lower dose of siRNA than a recent study,45 
demonstrating the high efficacy of NPSC/si_TNF-α for RNAi in vivo. Importantly, there 
was no significant difference in serum TNF-α level between PBS and NPSC/si_Scr 
injected mice, indicating that NPSC/siRNA nanoparticles were highly biocompatible, and 
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attenuation of the severity of LPS-induced inflammation in vivo only resulted from the 
specificity of RNAi. At a concentration of 5 mg/kg LPS, the generation of TNF-α was 
significant and robust, but there was no noticeable production of blood TNF-α at a lower 
concentration LPS treatment (10 µg/kg). Additionally, the pre-treatment of NPSC/siRNA 
did not exhibit detectable change of blood TNF-α compared to the control mice. 
Collectively, our results indicate that LPS-induced TNF-α secretion and 
inflammation can be efficiently suppressed by in vivo delivery of NPSCs/siRNA 
targeting TNF-α. Given the excellent targeting ability of NPSC/siRNA to the spleen, we 
speculated that the potent systematic TNF-α knockdown resulted from the efficient 
delivery of siRNA to macrophages in the spleen, which ultimately lead to TNF-α 
depletion in the LPS-induced mouse inflammation model. 
6.3. Conclusions 
In summary, we have shown that NPSCs are a highly effective and biocompatible 
platform for spleen targeted siRNA delivery and immunomodulation in vivo. The direct 
cytosolic delivery of siRNA to macrophages, coupled with the excellent targeting ability 
of NPSCs/siRNA to the spleen, contributes to potent RNAi in vivo, enabling highly 
efficient silencing of proinflammatatory cytokines with a total siRNA dose as low as 0.56 
mg/kg. These findings overcome a critical barrier in in vivo siRNA delivery, significantly 
enhancing the prospect of using therapeutic siRNA for autoimmunity and other 
inflammatory diseases. 
6.4. Experimental Section 
General method: All reagents or chemicals used were purchased from Fisher 
Scientific or Sigma-Aldrich. Chloroauric acid used for gold nanoparticle synthesis was 
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bought from Strem Chemicals Inc. (Newburyport, MA). si_GADPH and si_TNF-α with 
the following sequence, 5’-CAAGAGAGGCCCUAUCCCA[dT][dT]-3’(sense strand); 
and 5'-GUCUCAGCCUCUUCUCAUUCCUGct-3’ (sense strand), respectively, were 
synthesized by Sigma-Aldrich. Scramble siRNA (sense strand: 5’-
UUCUCCGAACGUGUCACGU-3') and Cy3-labeled scramble siRNA, were both 
purchased from Life Technologies (Carlsbad, CA). Confocal microscopy images were 
obtained on a Eclipse Ti-E microscope using a 40X objective. Flow cytometry analysis 
was performed on a BD LSR-II flow cytometer equipped with FACSDiva (BD Sciences, 
USA) by counting 10000 events. 
NPSC/siRNA preparation: The arginine-functionalized AuNP (Arg-AuNP) and 
NPSC were synthesized according to our previous report.28 Briefly, 1 μL of linoleic acid 
was mixed with 500 μL of phosphate buffer (5 mM, pH = 7.4) containing 1 μM Arg-
AuNP and agitated by an amalgamator at 5000 rpm for 100 s to form emulsions. Then, 10 
μL of the emulsion was added into 90 μL of 5 mM phosphate buffer containing pre-
mixed 2.5 μM Arg-AuNP  and 1 μM siRNA and incubated for 10 min. at room 
temperature to afford NPSC/siRNA complex. 
Cell culture: RAW 264.7 cells were purchased from American Type Culture 
Collection (ATCC, Manassas, VA). The cells were cultured at 37 °C under a humidified 
atmosphere of 5% CO2. Roswell Park Memorial Institute media (RPMI 1640) 
supplemented with 10% fetal bovine serum, 1% antibiotics (100 µg/ml penicillin and 100 
µg/ml streptomycin) and sodium pyruvate, was used for cell culture. Under the above 
culture conditions, the cells were subcultured once every four days. 
Cytotoxicity of NPSC/siRNA complex: RAW 264.7 cells (2.0 × 105 cells) were 
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seeded in a 48-well plate 24 h prior to the experiment. At the day of experiment, cells 
were washed by cold PBS and treated with varied concentration of NPSC and scramble 
siRNA complexes for 2 h, followed by an incubation of additional 24 h with fresh culture 
medium. The cell viability was determined using Alamar Blue assay reagent (Invitrogen, 
CA) according to manufacturer’s instruction. Three biological replicates were performed 
for viability determination. 
Fluorescently labeled Cy3-siRNA delivery: For confocal laser scanning 
microscopy (CLSM) imaging of the cellular uptake of NPSC/siRNA complex, RAW 
264.7 cells (4.0 × 105 cells) were seeded in each well of a 4 chamber Lab-Tek II 
chambered coverglass system (Nunc, NY) one day prior to the experiment. At the day of 
delivery, the culture medium was removed and replaced with Opti-MEM containing 40 
nM NPSC/Cy3-siRNA, followed by 1 h of incubation at 37 °C. After removing medium, 
the cells were washed once with cold phosphate buffer saline, fluorescence imaging was 
performed in PBS using an Eclipse Ti-E microscope. For flow cytometry analysis, RAW 
264.7 cells (4.0 × 105 cells) were seeded in a 24-well plate for 24 h prior to delivery, and 
the cells were washed with PBS for three times before siRNA delivery. At the day of 
transfection, various concentrations of siRNA formulations were added to cells and 
incubated for 2 h in Opti-MEM, The cells were harvested and resuspended in PBS for 
flow cytometry analysis on FACS LSR II (BD Biosciences). Cells suspensions were 
analyzed under the same parameter setting, and at least 10000 events were analyzed for 
each sample. 
In vitro TNF-α knockdown: RAW 264.7 cells (2.0 × 105 cells/well) were 
cultured in a 48-well plate for 24 h prior to the experiment. At the day of experiment, 
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cells were washed by cold PBS and treated with PBS, NPSC/si_TNF-α complexes at 
indicated si_TNF-α concentration, NPSC/si_Scr (40 nM), and free si_TNF-α (40 nM) for 
24 hours, followed by 3 hours LPS stimulation (1 µg/mL). At the end of incubation, 
culture media was collected for TNF-α level measurement by ELISA (R&D Systems, 
MN, USA). The silencing efficiency was denoted as the percentage of TNF-α levels of 
the control cells without nanoparticle treatment. Experiments were performed in 
triplicate. 
Animal care:  All animal experiments were conducted in accordance with the 
guidelines of Institutional Animal Care and Use Committee (IACUC) at University of 
Massachusetts Amherst.  Female BALB/c mice at least 6 weeks of age used for 
biodistribution and GAPDH knockdown study, and TNF-α knockdown study were 
purchased from The Jackson Laboratory (Bar Harbor, ME), and generously provided by 
Prof. Michelle Farkas (University of Massachusetts Amherst), respectively. All mice 
were allowed to rest at least one week in the animal facilities before any procedure was 
performed. Food and water intake were assessed. 
In vivo gene silencing: After one week of acclimatization, Female BALB/c mice 
at least 6 weeks of age, received lateral tail vein injections of PBS (negative control), or 
NPSC containing either non-targeting siRNA (NPSC/si_SCr), or anti-GAPDH siRNA 
(NPSC/si_GADPH), or anti-TNF-α siRNA (NPSC/si_TNF-α) diluted in PBS at a volume 
of 0.01 ml/g. For biodistribution and GADPH knockdown study, BALB/c mice were i.v. 
injected twice with NPSC/siRNA complexes at a siRNA dose of 0.14 mg/kg at a 2 day 
interval, blood and organs were collected and harvested 3 days after final injection. Blood 
was centrifuged in serum separator tubes at 5,000 r.p.m. for 10 min, and the supernatant 
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serum was carefully collected for TNF-α and IFN-γ analysis by ELISA (R&D Systems, 
MN, USA). Serum total bilirubin, alkaline phosphatase, aspartate aminotransferase, and 
alanine aminotransferase were measured using commercial kits (Teco Diagnostics, 
Anaheim, CA). 
For TNF-α knockdown study, BALB/c mice were i.v. injected twice with 
NPSC/siRNA complexes at a siRNA dose of 0.28 mg/kg at a 6 hour interval, followed by 
LPS (10 µg/kg or 5 mg/kg, i.p.) 24 hours later. Serum TNF-α was measured by ELISA 
1.5 hours after administration of LPS.  
Real Time Polymerase Chain Reaction (RT-PCR) analysis: Once mice were 
sacrificed, organs including spleen, liver, lung, kidney, and heart were harvested, cut into 
small pieces, washed with saline, and homogenized with Trizol reagent. RNA extraction 
was performed. Briefly, approximately 1.5 μg of RNA was isolated using the Pure Link 
RNA Mini kit (Ambion) following the manufacturer’s instructions. Superscript IV 
reverse transcriptase was used for conversion of approximately 150 ng of RNA to cDNA, 
along with RNaseOut, 10 mM dNTPs, and 50 μm random hexamers (Thermo Fisher 
Scientific), also following manufacturer’s instructions. RT-PCR was performed on cDNA 
as prepared above using a CFX Connect Real Time System with iTaq Universal SYBR 
Green Supermix (Biorad). All DNA primers were purchased from Integrated DNA 
Technologies (Caralville, Iowa). The following sequences were used: GAPDH Forward 
(5’-ACC ACA GTC CAT GCC ATC AC-3’), Reverse (5’-TCC ACC ACC CTG TTG 
CTG TA-3’); β-actin Forward (5’-GAT CAG CAA GCA GGA GTA CGA-3’), Reverse 
(5’- AAA ACG CAG CTC AGT AAC AGT C-3’). Three biological replicates were 
performed for each control group and three technical replicates were used for each 
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biological replicate. All GAPDH mRNA measurement was normalized to β-actin, with 
the NPSC/si_GAPDH values presented relative to the NPSC/si_Scr controls. 
ICP-MS sample preparation and conditions: Each harvested organ was 
weighed and transferred to metal ion-free tubes, followed by overnight digestion using a 
3:1 (v/v) mixture of HNO3 (68%) and H2O2 (30%). On the next day, ~ 0.5 mL of fresh 
aqua regia was added,  the sample was then diluted to 10 mL with de-ionized water 
(Highly corrosive aqua regia must be added with extreme caution!). A series of standard 
solutions (gold concentration: 20, 10, 5, 2, 1, 0.5, 0.2, 0 ppb) was prepared for each 
experiment. The ICP-MS analyses were performed on a Perkin-Elmer NexION 300X ICP 
mass spectrometer. 197Au was measured under standard mode. Operating conditions are 
listed as below: nebulizer flow rate: 0.95-1 L/min; rf power: 1600 W; plasma Ar flow 
rate: 18 L/min; dwell time: 50 ms. 
6.5. References 
 
1. Medzhitov, R. Nature 2008, 454, 428-435. 
 
2. Chovatiya, R.; Medzhitov, R. Mol. Cell. 2014, 54, 281-288. 
 
3. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Nature 2008, 454, 436-444. 
 
4. Galli, S. J.; Tsai, M.; Piliponsky, A. M. Nature 2008, 454, 445-454. 
 
5. Leuschner, F.; Dutta, P.; Gorbatov, R.; Novobrantseva, T. I.; Donahoe, J. S.; Courties, 
G.; Lee, K. M.; Kim, J. I.; Markmann, J. F.; Marinelli, B.; Panizzi, P.; Lee, W. W.; 
Iwamoto, Y.; Milstein, S.; Epstein-Barash, H.; Cantley, W.; Wong, J.; Cortez-Retamozo, 
V.; Newton, A.; Love, K.; Libby, P.; Pittet, M. J.; Swirski, F. K.; Koteliansky, V.; 
Langer, R.; Weissleder, R.;  Anderson, D. G.; Nahrendorf, M. Nat. Biotechnol. 2011, 29, 
1005-1010.  
 
6. Czapski, G. A.; Cakala, M.; Chalimoniuk, M.; Gajkowska, B.; Strosznajder, J. B. J. 
Neurosci. Res. 2007, 85, 1694-1703. 
 
 
 127 
 
7. Feldmann, M.; Maini, R. N. Annu. Rev. Immunol. 2001, 19, 163-96. 
 
8. Gordon, S.; Taylor, P. R. Nat. Rev. Immunol. 2005, 5, 953-964. 
 
9. Geissmann, F.; Manz, M. G.; Jung, S.; Sieweke, M. H.; Merad, M.; Ley, K. Science 
2010, 327, 656-661. 
 
10. Tabas, I.; Glass, C. K. Science 2013, 339, 166-172. 
 
11. Maeda, A.; Kawamura, T.; Ueno, T.; Usui, N.; Eguchi, H.; Miyagawa, S. Transpl. 
Immunol. 2013, 29, 76-81. 
 
12. Shealy D. J; Visvanathan, S. Handb. Exp. Pharmacol. 2008, 181, 101-129. 
 
13. Kodama, S.; Davis, M.; Faustman, D. L. Cell Mol. Life Sci. 2005, 62, 1-13. 
 
14. Aouadi, M.; G. Tesz, J.; Nicoloro, S. M.; Wang, M.; Chouinard, M.; Soto, E.; Ostroff, 
G. R.; Czech, M. P. Nature 2009, 458, 1180-1184. 
 
15. Peer, D.; Park, E. J.; Morishita, Y.;  Carman, C. V.; Shimaoka, M. Science 2008, 319, 
627-630. 
 
16. Pauley, K. M.; Cha, S. RNAi Therapeutics in Autoimmune Disease. Pharmaceuticals 
2013, 6, 287-294. 
 
17. Heo, M. B.; Lim, Y. T. Biomaterials 2014, 35, 590-600. 
 
18. Zheng, X.; Vladau, C.; Zhang, X.; Suzuki, M.; Ichim, T. E.; Zhang, Z. X.; Li, M.; 
Carrier, E.; Garcia, B.; Jevnikar, A. M.; Min, W. P. Blood 2009, 113, 2646-2654. 
 
19. Kortylewski, M.; Swiderski, P.; Herrmann, A.; Wang, L.; Kowolik, C.; Kujawski, M.; 
Lee, H.; Scuto, A.; Liu, Y.; Yang, C.; Deng, J.; Soifer, H. S.; Raubitschek, A. ;Forman, 
S.; Rossi, J. J.; Pardoll, D. M.; Jove, R.; Yu, H. Nat. Biotechnol. 2009, 27, 925-932. 
 
20. Howard, K. A.; Paludan, S. R.; Behlke, M. A.; Besenbacher, F.; Deleuran, B.; Kjems, 
J. Mol. Ther. 2009, 17, 162-168. 
 
21. Whitehead, K. A.; Langer, R.; Anderson, D. G. Nat. Rev. Drug Discovery 2009, 8, 
129-138. 
 
22. Gilleron, J.; Querbes, W.; Zeigerer, A.; Borodovsky, A.; Marsico, G.; Schubert, U.; 
Manygoats, K.; Seifert, S.; Andree, C.; Stöter, M.; Epstein-Barash, H.; Zhang, L.; 
Koteliansky, V.; Fitzgerald, K.; Fava, E.; Bickle, M.; Kalaidzidis, Y.; Akinc, A.; Maier, 
M.; Zerial, M. Nat. Biotechnol. 2013, 31, 638-646. 
 
 128 
 
23. Wang, Y. H.; Huang, L. Nat. Biotechnol. 2013, 31, 611-612. 
 
24. Jiang, Y.; Huo, S.; Hardie, J.; Liang, X. J.; Rotello, V. M. Expert Opin. Drug Deliv. 
2016, 13, 547-559. 
 
25. Liu, J.; Zhou, J. H.; Luo, Y. Bioconjugate Chem. 2012, 23, 174-183.  
 
26. Liu, J.; Gu, C.; Cabigas, E. B.; Pendergrass, K. D.; Brown, M. E.; Luo, Y.; Davis, M. 
E. Biomaterials 2013, 34, 3729-3736. 
 
27. Wang, M.; Alberti K.;, Varone, A.; Pouli, D.; Georgakoudi, I.; Xu, Q. Adv. Health. 
Mater. 2014, 3, 1398-1403. 
 
28. Jiang, Y.; Tang, R.; Duncan, B.; Jiang, Z.; Yan, B.; Mout, R.; Rotello, V. M. Angew. 
Chem. Int. Ed. 2015, 127, 516-520. 
 
29. Shah, B.; Yin, P. T.; Ghoshal, S.; Lee, K. B. Angew. Chem. Int. Ed. 2013, 52, 6190-
6195.  
 
30. Lu, H.; Wang, D.; Kazane, S.; Javahishvili, T.; Tian, F.; Song, F. A. Sellers, B. 
Barnett, P. G. Schultz, J. Am. Chem. Soc. 2013, 135, 13885-13891. 
 
31. Bruggen, T. V. D.; Nijenhuis, S.; Raaij, E. V.; Verhoef, J.; Asbeck, B. S. V. Infect. 
Immun. 1999, 67, 3824-3829.  
 
32. MacKenzie, S.; Ferna` ndez-Troy, N.; Espel, E. J. Leukoc. Biol. 2002, 71, 1026-1032. 
 
33. Joseph, R.; Srivastava, O. P.; Pfister, R. R. Mol. Vis. 2014, 20, 593-605.  
 
34. Barber, R. D.; Harmer, D. W.; Coleman, R. A.; Clark, B. J. Physiol. Genomics 2005, 
21, 389-395. 
 
35. Yan, B.; Kim, S. T.; Kim, C. S.; Saha, K.; Moyano, D. F.; Xing, Y.; Jiang, Y.; 
Roberts, A. L.; Alfonso, F, S.; Rotello, V. M.; Vachet, R. W. J. Am. Chem. Soc. 2013, 
135, 12564-12567. 
 
36. Chen, H.; Dorrigan, A.; Saad, S.; Hare, D. J.; Cortie, M. B.; Valenzuela, S. M.  PLoS 
One. 2013, 8, e58208. 
 
37. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M. J. Nat. 
Biotechnol. 2011, 29, 341-345.  
 
38. Wu, W.; Hodges, E.; Redelius, J.; Höög, C.  Nucleic Acids Res. 2004, 32, e17. 
 
 
 129 
 
39. Blanco, E.; Shen, H.; Ferrari, M. Nat. Biotechnol. 2015, 33, 941-951.  
 
40. De Villiers Melgardt, M.; Aramwit, P.; Kwon, G. S. New York, NY: Springer, 2009. 
Print. 
 
41. Whitehead, K. A.; Dorkin, J. R.; Vegas, A. J.; Chang, P. H.; Veiseh, O.; Matthews, J.; 
Fenton, O. S.; Zhang, Y.; Olejnik, K. T.; Yesilyurt, V.; Chen, D.; Barros, S.; Klebanov, 
B.; Novobrantseva, T.; Langer, R.; Anderson, D. G. Nat. Commun. 2014, 5, 4277. 
 
42. Blanque´, R.; Meakin, C.; Millet, S.; Gardner, C. R. Gen. Pharmac. 1998, 31, 301-
306. 
 
43. Yin, L.; Song, Z.; Qu, Q.; Kim, K. H.; Zheng, N.; Yao, C.; Chaudhury, I.; Tang, H.; 
Gabrielson, N. P.; Uckun, F. M.; Cheng, J. Angew. Chem. Int. Ed. 2013, 52, 5757-5761. 
 
44. He, H.; Zheng, N.; Song, Z.; Kim, KH.; Yao, C.; Zhang, R.; Zhang, C.; Huang, Y.; 
Uckun, F. M.; Cheng, J.; Zhang, Y.; Yin, L. ACS Nano, 2016, 10, 1859-1870. 
 
45. Kim, S. S.; Ye, C.; Kumar, P.; Chiu, I.; Subramanya, S.; Wu, H.; Shankar, P.; 
Manjunath, N. Mol. Ther. 2010, 18, 993-1001. 
 
46. Lee, S. J.; Lee, A.; Hwang, S. R.; Park, J. S.; Jang, J.; Huh, M. S.; Jo, D. G.; Yoon, S. 
Y.; Byun, Y.;  Kim, S. H.; Kwon, I. C.; Youn, I.; Kim, K. Mol. Ther. 2014, 22, 397-408. 
 130 
CHAPTER 7 
ENGINEERING THE SIZE AND CHARGE ORIENTATION OF GOLD 
NANOPARTICLE TO OPTIMIZE ANTIMICROBIAL ACTIVITY   
 
7.1. Introduction 
Pathogenic bacteria have become a serious threat to public health, with acquired 
antibiotic resistance challenging the effectiveness of traditional antimicrobials. 
Nanoparticles (NPs) present attributes that make them promising antimicrobial agents.1 
For example, the high surface area to volume ratio of NPs enables the efficient 
encapsulation/conjugation of antibiotics.2 Cationic nanoparticles provide self-therapeutic 
anti-microbial systems that function through bacterial membrane penetration and 
disruption.3 These positively charged NPs, however, can possess substantial toxicity to 
mammalian cells, including hemolytic activity.4 Integrating neutral zwitterionic ligands 
into cationic nanoparticles has created a new class of NP-based antimicrobial that can 
decrease mammalian cells toxicity and maintain antifouling properties.5 Activity in these 
systems, however, requires careful balancing of zwitterionic and cationic ligands to 
ensure the stability and antibacterial activity of the nanoparticles.4a, 6 
In addition to surface functionalization, there is mounting evidence indicating that 
the size of NPs also plays a significant role in determining the bactericidal activity of 
NPs.7 For example, we have previously found that cationic gold nanoparticles (AuNP) 
displayed very different interaction patterns with bacterial membrane between 2 nm and 6 
nm core sizes.8 This strikingly different behavior suggested that perhaps size-dependent 
antimicrobial behavior might be observed with zwitterionic particles as well. 
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Figure 7.1. A) Chemical structure of zwitterionic ligands used for AuNP synthesis. 
Zwitterionic headgroups were conjugated to a non-interacting oligo(ethylene glycol) -
functionalized interior. B) The minimum inhibitory concentration (MIC) of zwitterionic 
Au-SN and Au-NS NPs against Gram-negative (P. aeruginosa) and C) Gram-positive (A. 
azurea) bacterial strains. Bacteria were cultured overnight with NPs at concentrations and 
the experiment s repeated in triplicate. 
 
Here, we report the design and synthesis of a new family of zwitterionic NP-based 
antimicrobials. The antibacterial activity of these zwitterionic NPs was readily 
manipulated by finely tuning the core size of NPs. Small- NPs (2 nm core) display low 
antimicrobial activity. Surprisingly, modestly larger 6 nm core AuNPs exhibit very potent 
antimicrobial activity by disrupting the bacterial cell membrane. In addition, subtle 
tuning of the surface charge orientations of zwitterionic AuNPs results in a substantial 
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change of antimicrobial activity. Noteworthy, all these zwitterionic nanoparticles exhibit 
low toxicity to mammalian cells and maintain high hemocompatibility. The parametric 
engineering of NPs provides both new bactericidal therapeutics and insight into the 
coupled role of size and surface functionality on the antimicrobial activity. 
7.2. Results and Discussion 
Zwitterionic surface are known to inhibit bacterial adhesion and prevent biofilm 
formation.6b, 9 In this study, two sets of zwitterionic ligands were designed to synthesize 
monolayer-protected gold nanoparticles with high biocompatibility and potential 
bactericidal property. These zwitterionic ligands display different charge orientations 
(Figure 7.1A), one has positive charges in the outermost layer (SN), while the other one 
has the positive charge inside the ligand terminus (NS).  
 
Figure 7.2. TEM images of zwitterionic AuNPs with 2, 4, and 6 nm core size. 
 
Three sets of zwitterionic AuNPs with different core size were synthesized by 
reducing chloroauric acid in the presence of precisely controlled ratio of SN or NS 
ligand.10 With the molar ratio of gold salt to surface ligand increased from 1/3 to 3/1, 
AuNPs with core size of 2, 4, and 6 nm were obtained (Figure 7.2). Dynamic light 
scattering (DLS) analysis (Table 7.1) confirms the increased NP size under the different 
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reaction molar ratio. Additionally, zeta-potential measurements showed nearly neutral 
charges of both Au-NS and Au-SN NPs. The successful surface functionalization of 
nanoparticles with zwitterionic ligands was also analyzed and verified using laser 
desorption/ionization mass spectrometry (LDI-MS, Figure 7.3). Molecular peaks 
observed at m/z value of 530.2 and 601.1 were attributed to NS and SN ligands, 
respectively.  
Table 7.1. Dynamic light scattering analysis and zeta-potential measurements 
of as-synthesized nanoparticles in PB buffer. 
 
 
 
Figure 7.3. LDI-MS spectrum of zwitterionic gold nanoparticles with A) SN (m/z 601.1), 
and B) NS (m/z 530.2) ligand modifications. 
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Table 7.2. MIC values (nM) of zwitterionic NPs against Gram-negative (P. 
aeruginosa) and Gram-positive (A. azurea) bacterial strains.  
Nanoparticles 
MIC (nM) 
P. aeruginosa A. azurea 
2 Au-SN 8000 4000 
4 Au-SN 150 200 
6 Au-SN 50 100 
2 Au-NS 10000 8000 
4 Au-NS 600 800 
6 Au-NS 150 400 
 
We first evaluated the antimicrobial activities of these zwitterionic AuNPs against 
both Gram-positive and Gram-negative bacterial strains. Two model strains, P. 
aeruginosa (Pseudomonas aeruginosa, Gram-negative) and A. azurea (Amycolatopsis 
azurea, Gram-positive) were selected as they are pathogenic bacteria that show intrinsic 
resistance to a wide variety of antibiotics.11 The minimal inhibitory concentration (MIC) 
of each NP against these bacteria was determined using broth dilution method in the 
presence of nanoparticles of varying concentrations.12 As shown in Figure 7.1B and 7.1C, 
all zwitterionic NPs were able to completely inhibit the proliferation of P. aeruginosa and 
A. azurea. There was a significant effect of particle size on bacteria proliferation. As an 
example, the MIC concentration of Au-SN NP against Gram-negative P. aeruginosa 
decreased from 8000 nM to 50 nM, when the core size of NP was increased from 2 nm to 
6 nm. A similar trend was observed for the Gram-positive A. azurea strain (Table 7.2), 
with the 6 nm NP displaying a 40-fold lower MIC than the 2 nm analog, Surface structure 
likewise played a role in bactericidal efficacy: all of the Au-SN NPs were more effective 
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than these Au-NS analogs. Our finding is consistent with the previous study where 
cationic-terminated particles were shown more toxicity to both Gram-negative and Gram-
positive bacterial strains than anionic-terminated particles.4a Collectively, our study 
demonstrated that both the size and charge orientation of zwitterionic NPs are crucial in 
determining the antimicrobial properties of these zwitterionic NPs.  
 
Figure 7.4. Visualizing morphological changes in cell membranes using TEM. A) Gram-
negative (P. aeruginosa) and B) Gram-positive (A. azurea) bacterial strains were treated 
with 2, 4 and 6 nm Au-SN and Au-NS NPs at their MIC concentration for 3 h. Red 
arrows indicate the morphological changes of cell membrane structures with and without 
NPs treatment. Scale bars: 200 nm for black and 500 nm for white. 
 
Having demonstrated the distinct size- and charge orientation- dependent 
antimicrobial activity of zwitterionic AuNPs, we set out to understand the antibacterial 
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mechanism of these NPs. To this end, we treated P. aeruginosa and A. azurea with NPs 
at their respective MIC concentrations for 3 hours (Table 7.2), followed by examining the 
bacterial morphology and NP-bacterial membrane interaction using transmission electron 
microscopy (TEM). As shown in Figure 7.4, both Gram-negative and -positive strains 
without NPs treatment exhibit typical membrane structures, with single-layered or 
multilayered peptidoglycans easily identified.13  
 
Figure 7.5. Propidium iodide staining assays of Gram-negative (P. aeruginosa) bacterial 
strain after 3 h incubation with 6 nm zwitterionic NPs at each MIC concentration via 
confocal microscopy observation. 
 
The morphology and membrane integrity of the bacteria, however, were 
dramatically changed after NPs treatment in a size-dependent fashion. Smaller 2 nm NPs 
were randomly adsorbed on bacteria without inducing noticeable membrane changes. 
However, 4 and 6 nm NPs penetrated deeper into the peptidoglycan layer and anchored 
more strongly on the bacterial surface, with 6 nm NP attaching the most. Noteworthy, 
with more NP accumulation on the bacterial surface a higher degree of membrane 
damage was observed.  
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Figure 7.6. Propidium iodide staining assay of Gram-positive (A. azurea) bacterial strain 
after 3 h incubation with 6 nm zwitterionic NPs at MIC concentration. 
 
Moreover, some outer membrane vesicles (OMVs) began to form on the cell 
membrane after incubation with 4 nm Au-SN NP as denoted in Figure 7.4. This blebbing 
could be attributed to the NP aggregation formation on the bacterial surface as indicated 
by red arrows (Figure 7.4). More interestingly, we observed a higher efficiency of these 
NPs to disrupt Gram-negative P. aeruginosa. The existence of multilayered 
peptidoglycan with Gram-positive bacterium potentially passivated the interactions of 
NPs and bacterial membranes, leading to less NPs penetration and decreased toxicity of 
NPs against gram-positive bacteria. Au-NS NP displayed a similar interaction trend with 
P. aeruginosa and A. azurea, but with decreased bacteria disruption efficiency compared 
to that of Au-SN NP (Figure 7.4), indicating the positive charge terminated SN ligands 
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have stronger binding with negatively changed bacterial membrane. This observation 
correlates well with the MIC studies where Au-SN NP shows superior antimicrobial 
activities compared to that of Au-NS NP (Table 7.2).  
Having observed NPs-induced bacterial membrane distortions, we surmised that 
membrane damage induced by NPs provided their antimicrobial activities. To verify this 
hypothesis, we treated bacteria with the most potent 6 nm NPs, followed by propidium 
iodide (PI) staining to check the integrity of bacteria membrane. PI only leaks into cells 
with compromised membranes with concomitant enhanced fluorescence.2d, 3a As shown 
in Figure 7.5 and Figure 7.6, we only observed strong red fluoresce from bacterial cells 
treated with NPs, indicating the integrity of bacterial membrane was indeed disrupted by 
NPs.  
 
Figure 7.7. Cell viability assay of gold nanoparticles featuring different size and surface 
ligand on NIH-3T3 cells. NIH-3T3 cells were treated with each NP’s MIC concentration 
for 24 h. Mean values ± standard deviation, N = 3.  
 
The above studies demonstrate that the larger AuNPs are efficient bactericidal 
agents. Effective applications of antimicrobials in or on patients, however, require a low 
toxicity to mammalian cells, and in particular red blood cells (RBCs).2c, 14 To this end, we 
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first studied the toxicity of zwitterionic NPs against fibroblast 3T3 cells that have been 
widely used to determine the cytotoxicity and biocompatibility of antibacterial agents.15 
As shown in Figure 7.7, the treatment of 3T3 cells with AuNPs at individual MIC 
concentration had negligible cytotoxicity as measured by Alamar Blue assay. The 
hemolytic activity of these NPs against human red blood cells (RBCs) was also 
measured.5a, 16 As shown in Figure 7.8, at the concentrations we tested (up to 16-fold 
higher than the MIC concentration, with highest dosing determined by the high optical 
density of the AuNPs), none of the NPs show any observable hemolytic activity, 
demonstrating the intrinsic biocompatibility of zwitterionic ligands with mammalian cells 
and human blood cells. 
 
 
Figure 7.8. Hemolytic activity of gold nanoparticles featuring different size and surface 
ligand at different concentrations on human red blood cells (RBCs) for 30 min at 37 °C. 
Hemolysis (%) was calculated using water as a positive (+) control. RBCs incubated with 
PBS were used as negative (-) control. Error bars represent standard deviations (n = 3). 
 
7.3. Conclusions 
In summary, we have demonstrated an important synergy between NP core size, 
surface charge orientations, and antimicrobial behavior of zwitterionic gold nanoparticles. 
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We observed a dramatically increased antimicrobial property with increasing NP size, 
with changes of charge orientation also substantially contributing to antimicrobial activity. 
Significantly, all NPs maintained their intrinsic biocompatibility toward mammalian and 
in particular red blood cells, making these systems promising for antimicrobial 
therapeutic use. In a broader context, this study provide direct demonstration that subtle 
changes in NP size and surface functionality can dramatically alter the interactions of 
these materials with biosystems. 
7.4. Experimental Section 
Synthesis of nanoparticles: The procedure for 2, 4 and 6 nm zwitterionic gold 
nanoparticles synthesis was based on the Brust-Schiffrin method.11a, 20 Briefly, 
Chloroauric acid (5.0 mg, 0.013 mM) and zwitterionic ligand11c, 11d were dissolved in 7 
mL of methanol/acetic acid 6:1 (v/v). 100 μL of sodium borohydrate (10.0 mg, 0.27 mM) 
in ice-cold water was added dropwise with rapid stirring. After continuous stirring for 3 
h, nanoparticle solution was formed, and the solvent was then removed under vacuum at 
40 °C. The residues were dissolved in 10 mL de-ionized water, and the solution was then 
dialyzed (dialysis membrane, Thermo Scientific, MWCO=10000) for 72 h against de-
ionized water, which was changed every 8 h. 2, 4, and 6 nm particles were obtained via 
adjusting the molar ratio of chloroauric acid and zwitterionic ligand (1:3, 1:1 and 3:1, 
respectively). 
Characterization of as-prepared gold nanoparticles: The morphology of the 
Au NPs was examined using a FEI TecaniT12 microscope with an accelerating voltage of 
120 kV. Particle hydrodynamic diameter was measured on a Malvern Zetasizer (Nano 
series, Malvern Instruments Inc, USA) with a He-Ne laser (633 nm) and a backscattering 
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angle of 173º. Molecular peak of ligand was tested by MALDI-MS (Bruker Autoflex III 
MALDI-TOF MS, 200 shots-20 off-laser 55%, suppress up to 400Da).  
Mammalian cell viability assay: NIH-3T3 cells (ATCC CRL-1658) were 
purchased from American Type Culture Collection (ATCC, Manassas, VA) and 
maintained in Low-glucose Dulbecco's modified Eagle's medium (DMEM) with 10% 
fetal bovine serum (FBS) and 1% antibiotic (100 U/mL penicillin and 100 μg/mL 
streptomycin). Cells were cultured at 37 °C under a humidified atmosphere of 5% CO2 
(96-well plate, 10,000 cells/well). Media was removed and cells were washed with 
phosphate-buffered saline (PBS) before addition of NPs with each MIC concentration. 
Then, cells were incubated for another 24 h before cell viability determination using 
Alamar blue assay according to the manufacturer's protocol (Invitrogen Biosource). After 
incubation, 200 μL of solution from each wells was transferred in a 96-well black 
microplate and quantified (excitation/emission: 560 nm/590 nm) on a SpectroMax M5 
microplate reader (Molecular Device) to determine the cellular viability. Cells without 
any NPs treatment were normalized as 100%. Each experiment was performed in 
triplicate.  
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